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Newborn screening (NBS) is a mandatory public health program aimed at the early 
identification of babies with conditions that will benefit from early diagnosis and treatment. With 
increasing technology, some mandatory NBS programs have expanded to offer optional NBS for 
diseases for which there is limited treatment efficiency data. Little is known about the significant 
variables that influence parents’ decisions about optional NBS. This dissertation used Duchenne 
muscular dystrophy (DMD) as an exemplar to address whether variation in the presentation and 
characteristics of NBS tests influence decision making.  
Methods. 
In 3 randomized survey experiments using Internet samples, I explored the following 
factors that may motivate intended utilization of DMD NBS: 1) the bundling of mandatory NBS 
panels; 2) the provision of additional information about DMD NBS norms; 3) the mode of DMD 
NBS results release; 4) the overarching purpose of DMD NBS; and 5) the perceived risk of 
DMD. The primary outcome variable was intent to utilize DMD NBS with additional outcome 
variables of attitudes towards DMD NBS. I also explored the influence of these factors on 
attitudes towards DMD NBS using logistic regressions, and the influence of subjective norms 
and attitudes towards DMD NBS on DMD NBS intention. 
Results. 
 Study 1 findings showed that the presence of a context of mandatory NBS (bundled or 
unbundled) influenced DMD NBS intent and attitudes towards DMD NBS. When participants 
were not given the context of broader mandatory NBS in which to place a specific optional NBS, 
they were more hesitant to choose testing. Presenting additional subjective norm information did 
not influence DMD NBS intent, though for each study, participants’ own subjective norms did 
predict NBS. Studies 2 and 3 showed that neither the mode of results release nor the overall test 
purpose guiding the release were significant predictors when parents lacked any specific reason
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to believe their child was at risk. However, an interaction of results release and altruism showed 
that altruistic participants did not choose DMD NBS if their participation would have no societal 
implications. An interaction of DMD NBS purpose and perceived vulnerability showed that 
personal purpose increased DMD NBS intent when perceived vulnerability existed, but DMD 
NBS intent was relatively consistent regardless of perceived vulnerability when the test’s main 
purpose was research. Additional results indicated that medical mistrust is a significant predictor 
of DMD NBS. 
Conclusions.  
New parents are increasingly being faced with optional NBS decisions, yet there is no 
consistent policy regarding optional NBS communication, in terms of the information included 
and the way in which this information is presented. This dissertation explored whether variation 
in test presentation and characteristics influences optional NBS decision making. The results 
suggest that future optional NBS programs should be careful to present testing information in a 
way that explains how a single optional NBS test fits into overall mandatory NBS. Future 
recruitment in NBS programs should appeal to participants’ sense of altruism if, but only if, the 
participation will, in fact, be a contribution. Additionally, health professionals should attend to 
parents’ perceptions of their child’s vulnerability, which appears to be a broader construct than 
simply family history of a specific disease, as such perceptions influence DMD NBS decision 
making. Increasing attention to the influence of such structural factors and individual differences 
on optional NBS decision making will become more and more important as NBS programs are 






The time soon after the birth of a child can be a joyful, but often stressful, one for 
parents. Imagine a couple in their hospital room with their newborn child. The parents are 
concentrating on their newborn after an exhausting 24 hours with little sleep, and it seems like 
the nurse has been coming in constantly to talk about medical issues. The nurse now comes in to 
tell the parents about state-mandated newborn screening (NBS). In addition to this “heel-stick 
test”, the nurse informs the parents about an optional test, one that they can choose to or not to 
have done on their baby.  
The basic differences in mandatory and optional NBS raise questions about how similar, 
or different, these testing experiences are. While parents are not in a decision-making role 
regarding mandatory NBS panels, with the continued expansion of NBS, parents may be 
increasingly faced with the decision to utilize additional optional NBS. However there is no 
standard practice for delivering NBS information, in terms of the information included and the 
way in which this information is presented (Hargreaves, Stewart & Oliver, 2005; Loeben, Marteu 
& Wilfond, 1998). Thus there is a potential for the variation in presentation of and structure of 
NBS to influence parents’ decisions. For example, optional NBS requires separate attention and 
a conscious decision, even though it is done at the same time as mandatory tests. How optional 
NBS are presented to parents in the context of mandatory NBS is a potential influence, as is the 
way in which the results from optional NBS are released. There are multiple ways in which the 
NBS results can be released, each with varying degrees of accessibility to others. With varied
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guidelines for optional NBS, it is important to address these potential determinants; significant 
influences may lead to non-optimal outcomes such as disconcordance between desire for and 
utilization of NBS. 
What is Newborn Screening? 
Newborn screening (NBS) is a public health program that allows for early detection of 
disorders that would cause irreversible clinical damage if not recognized at birth (Therrell, 
2001). NBS is a mandatory part of pediatric care, describing a set of laboratory tests including 
metabolic, hematologic, and endocrinologic tests, as well as genetic analyses. The physical 
process of NBS begins between 24-48 hours after birth with a single blood sample taken from 
the baby’s heel, which is then dried onto filter paper. The blood is then sent to a laboratory for 
testing. Results are returned within one week and additional testing is done in the case of positive 
results.  
NBS was first successful in Massachusetts in 1962 with screening for Phenylketonuria 
(PKU) and serves as a foundation for future NBS (Guthrie & Susi, 1963). PKU is a metabolic 
disease resulting from an enzyme deficiency. In the 1950s a special diet was developed to 
prevent the severe retardation that often results from PKU, and a decade later an assay to test for 
the disease was introduced (Alexander, 2003; Centerwall & Centerwall, 2000). Thus there was a 
clear justification for PKU NBS: babies benefit from early detection and treatment of the disease. 
Starting in the mid-1970s, NBS panels expanded to include other genetic disorders (McCabe, 
Therrell, Larson & McCabe, 2002) and expanded NBS has seen a high compliance rate (Liebl et 
al., 2002). Generally, expanded NBS is still limited to conditions that benefit from early 
diagnosis and early treatment (Centers for Disease Control National Center on Birth Defects and 
Developmental Disabilities [NCBDDD] 2004).  
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The NBS expansion was significantly aided by the development of tandem mass 
spectrometry technology, which made it possible to screen for multiple disorders using one blood 
sample at incremental cost while reducing the rate of false positives (Carroll & Downs, 2006; 
Insinga, Laessig & Hoffman, 2002; Levy, 1998; Schoen, Baker, Colby & To, 2002). Due to this 
routinization of tandem mass spectrometry technology, between 1995 and 2005 the average U.S. 
state added 19 tests for treatable disorders to its NBS program (Tarini, Christakis & Welch, 
2006). However there is significant variation in public health programs in the U.S. and 
internationally regarding the number and types of conditions for which NBS is conducted 
(Clayton, 1999; Comeau et al., 2004; McCabe et al., 2002; Therrell Johnson & Williams, 2006). 
In response to this variation, in 2005 the American College of Medical Genetics argued for a 
uniform NBS panel with 29 core disorders and 25 additional secondary disorders to be used in 
newborn screening programs in all U.S states (The American College of Medical Genetics, 
2006). Despite this report, each state has an NBS program with a panel of mandatory tests that 
screen for anywhere from 30 to 55 conditions (National Newborn Screening and Genetics 
Resource Center, 2012). These variations are due to test efficacy, program support, and local 
advocacy (Moyer et al., 2008).  
While NBS programs are widespread, one barrier in offering consistent programs is the 
significant divisions in how geneticists approach NBS. One side of stakeholders views NBS as a 
successful example of public health that should be continued as a population-level public health 
service (Green, Dolan & Murry, 2006; Marsden, Larson & Levy, 2006), while the other side 
desires evidence-based research to guide NBS education practices (Hoff, Hoyt, Therrell & 
Ayoob, 2006; Kenner & Moran, 2005; Sewell, Gebhardt, Herwig & Rauterberg, 2004) and more 
evaluation research in order to offer an evidence-based NBS test, especially for tests that do not 
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offer treatment implications and should be voluntary (Botkin et al., 2006; Dhondt, 2007; Ross, 
2006). This division led to recent panel of experts headed by the Secretary's Advisory Committee 
on Heritable Disorders in Newborns and Children ([SACHDNC], 2012) which recommended 
that a specific NBS should be considered for addition to mandated NBS panels only if the 
following conditions are met:  
1) The disease can be identified at a period of time (24 to 48 hours after birth) at which it 
would not ordinarily be clinically detected.  
2) A test with appropriate sensitivity and specificity is available.  
3) There are demonstrated benefits of early detection, timely intervention, and efficacious 
treatment.  
Despite the SACHDNC criteria, NBS policy is not settled. NBS programs are likely to continue 
expanding, increasingly including diseases for which limited information about treatment 
efficacy is available at minimal incremental cost (Carroll & Downs, 2006; Insinga et al., 2002; 
Schoen et al., 2002). 
What is Optional Newborn Screening? 
The basic objective of NBS is to identify babies with pre-symptomatic conditions that 
will benefit from early diagnosis and preventive treatment (Levy & Albers, 2000). But with 
technological advances, more and more types of genetic testing are becoming available, even if 
the implications of the results of these tests are unclear. Thus there are two different sets of NBS: 
mandatory and optional. The core difference of mandatory and optional tests is that there is no or 
limited data on treatment efficacy of optional NBS, and no improvement in clinical outcomes. 
Optional NBS is typically available as pilot programs to identify potential biomarkers or 
treatment for newborn diseases and/or improve future NBS evaluation (Pass et al., 2006), but 
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often have no immediate implications for those being tested, such as personal behavior changes 
or medical treatment, depending on the disorder. For example, in 1997 the Massachusetts 
Department of Public Health developed an optional pilot NBS program for 20 additional 
disorders including rare metabolic diseases (Atkinson et al., 2001). Mandatory NBS is 
consistently found to be almost universal (Bradley et al., 1993; Clayton, 2005; Liebl et al., 2002; 
Therrell et al., 2006), and even optional NBS see utilization rates as high as 90% (Bradley et al., 
1993; Campbell & Ross, 2003; Dhondt, 2005). However, debates have arisen with the 
development of optional NBS.  
Ethical concerns about NBS for disorders with no proven treatment efficacy include the 
use of information and the consent process. The consent process of NBS varies by state and by 
type of NBS (mandatory or optional). Mandatory NBS does not require a formal consent process 
and is often done without parental awareness (Campbell & Ross, 2003; Davis et al., 2006); in the 
recent past only three U.S. states required parents’ signed consent (Mandl, Feit, Larson & 
Kohane, 2002) and an opt-out option exists in 27 states either by verbally refusing screening or 
signing a waiver refusing screening for religious or other reasons (Mandl et al., 2002). Optional 
NBS involves discussions between parents and healthcare providers and requires explicit consent 
from parents. The requirement for consent is important because it means that how a test is 
offered could affect whether or not is done. For example, one criticism offered by new parents is 
that physicians often inform them about optional NBS decisions just after birth, when they are 
tired and distracted, instead of before birth, when they would have had a greater opportunity to 
learn about the disease and the NBS process (Campbell & Ross, 2003).  
The combination of advancing technology and parent and provider advocacy has pushed 
for an increase in optional NBS (Pass et al., 2006). However questions arise about the 
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presentation and characteristics of specific NBS tests, and they influence of these attributes on 
choice and attitudes.  
How is Optional NBS Presented in the Context of Mandatory NBS Panels? 
Optional NBS is generally not done in isolation; it is done in conjunction with mandatory 
NBS panels. For example, in the Massachusetts screening program parents are asked to 
participate in optional NBS before the blood specimen is sent to the lab for mandatory NBS 
(New England Newborn Screening Program). The parents’ participation is recorded on the blood 
specimen collection form (parents received a copy of the form). It is crucial, then, to know 
whether the coupling of optional NBS with mandatory NBS influences parental decision making.   
When presented with multiple pieces of information people value each piece less than 
they do the same information presented in an overall cluster, clustering information increasing 
the value of that information (Koszegi & Rabin, 2009). Researchers have asserted that people 
prefer one piece of clustered information versus multiple pieces of information (Koszegi & 
Rabin, 2009). This clustering is similar to bundling, the strategy of marketing two or more 
products or services in particular combinations (Wilson, 1997). Bundling is most commonly 
observed in the marketing of complementary products, such as a cable TV + internet plan versus 
separately bought plans (Venkatesh & Mahajan, 2009). NBS can be seen as a situation in which 
multiple products exist – optional and mandatory NBS. In this case there are two ways of 
presenting NBS to parents: 1) unbundled (presenting each NBS test separately); and 2) bundled 
(presenting the NBS tests as one single product).  
Bundling may affect the utilization of optional NBS by manipulating the attention given 
to the optional tests versus the mandatory NBS test panel. A qualitative study found that when 
parents went through a separate invitation process for an optional NBS test (as opposed to a 
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single occasion that included the optional NBS test offer at the same time as the mandatory NBS 
tests), utilization of NBS was affected (Moody & Choudry, 2011). This concept of separating the 
optional and mandatory NBS steps may also apply to the context of mandatory NBS alone; a 
similar effect may be seen in the bundling/unbundling of mandatory NBS test panel. 
Additionally, what has previously been described as ‘sequential location’ (Pilnick, 2008), or the 
way a NBS test is closely related in proximity to other more routine tests, can be thought of as 
bundling. Because optional tests are presented with a panel of mandatory NBS tests, an 
unbundled mandatory NBS test panel may divide the decision makers’ attention and make it 
harder to focus on the single decision at hand – the optional NBS.  
What Happens to the Information from NBS?   
When making the decision to utilize optional NBS, parents may also take into account 
what happens after the test: what happens with the results and how much control do they have 
over that information? Currently, NBS results (mandatory or optional) information is typically 
given to medical professionals, who then share the results with parents and enter them in medical 
records that parents can access. In 46 states the results from mandatory NBS are released to the 
birth hospital (Mandl et al., 2002), however information from mandatory NBS results is available 
to multiple other sources, which has implications for the usage of this information in the future. 
Parents often report not knowing that the mandatory NBS testing process typically involves state 
health departments instead of a private laboratory or the hospital laboratory and feeling 
“blindsided” by that knowledge (Davis et al., 2006). But increasingly, such as in California, 
private sector laboratories are becoming involved in NBS (California Department of Public 
Health, 2010). Although these laboratories are public-private partnerships that involve the state-
run mandatory NBS programs, there also exist for-profit private genetic testing companies that 
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can perform optional NBS and provide these results to individuals (McCandless, 2004; Tarini, 
2007). NBS information (either mandatory or optional) can also be used for treatment and 
research. This information is typically collected from residual blood specimens and stored in 
biobanks. Finally, numerous registries allow such NBS information to be tracked for public 
health purposes. Each optional NBS release policy may inform parents’ anticipated control over 
the test results, which may in turn influence their decision to utilize the test in the first place.  
In the case of optional NBS, pediatricians (or the primary medical care giver) and parents 
usually have access to the information regardless of whoever else might see it. However, 
sometimes NBS information is released privately, which grants parents complete control over the 
information, including whether, and with whom, to share it. Although there is no research 
addressing the patterns of patients sharing privately-released genetic information with their 
physicians, previous research has addressed influences on, and consequences of disclosing such 
information to other family members for whom the results also have implications. Research 
about the social and psychological consequences associated with revealing the inheritance of a 
genetic disease has shown that sharing test results can increase tension between family members 
(Metcalfe 2008) and worry about future children’s health (Weil, 2002). Family members are 
sometimes blamed for genetic disabilities (James et al., 1996), often by the other parent (Weiss, 
1981). Bailey et al addressed a deeper ethical issue about disclosing genetic test results to family 
members - the lack of their explicit informed consent when the test results may present unwanted 
information about themselves (Alpert, 2003; Bailey, Jr. et al., 2009).  
Once the NBS information is released to physicians, the test information is often entered 
into an electronic health records (EHR) accessible to current and future medical providers, 
thereby increasing care coordination. EHRs are also meant to give patients more control over 
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their medical information because they are able to access that information themselves (Wynia & 
Dunn, 2010). EHRs have general public support: recent studies have shown that approximately 
87% of Americans believe that EHRs could improve medical care quality and efficiency (Westin 
& Markle Foundation, 2008) and almost 50% express interest in using one, even stating that they 
would pay to use EHRs (Vishwanath, 2009). However in 2010 only 2.7% of people were 
actually using an EHR (Westin & Markle Foundation, 2008) and privacy concerns are credited 
with preventing common utilization (Vishwanath, 2009; Westin & Markle Foundation, 2008). 
These privacy concerns focus mainly on sharing medical test results (Ball, Smith & Bakalar, 
2007), and are partly due to the unease over others accessing and using data from EHRs to 
discriminate against (Grossman, Zayas-Caban & Kemper, 2009).   
Privacy concerns may be even more pronounced with NBS: the parent is acting as a 
proxy decision maker and the test results have long-term implications for other family members 
who may be worried about future discrimination by health insurers (Tabor et al., 2011). 
Currently, NBS results are most often given directly to the physician and he or she is responsible 
for reporting them to the parents. Although patients’ EHR utilization is low, the push to move 
personal health records to an electronic system is increasing. Therefore it is worth considering 
what might happen if NBS results were automatically entered into an EHR by the physician, an 
unstudied matter thus far. The concerns that accompany the use of EHRs may then influence the 
decision whether or not to utilize NBS, making the information from the test visible to medical 
professionals. 
NBS programs often utilize biobanks of residual blood specimens (RBS); 14 NBS 
programs that serve almost half of all U.S. births save RBS for at least 21 years (Therrell & 
Hannon, 2012). For example, Michigan maintains a statewide biobank of newborn blood spots 
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which have been collected and archived on all live births in the state since 1985 (The Michigan 
Neonatal Biobank). In the case of RBS the control a parent has over the information from that 
particular NBS test is loosened because he/she typically does not know what that RBS would be 
used for. The use of RBS for research is a controversial topic. Most studies have found that 
parents are willing to let RBS be used for research, especially if permission is explicitly obtained 
(Botkin et al., 2012; Davey, French, Dawkins & O’Leary, 2005; Tarini et al., 2010), and an 
overall belief in research is cited as a reason for accepting NBS (Parsons, Israel, Hood & 
Bradley, 2006). Previous research has revealed five influences on parental support for research 
using RBS: 1. Avoiding harm to their child; 2. Time and convenience; 3. Altruism; 4. 
Participation incentive; and 5. Relevancy of the study to their family (Tabor et al., 2011). There 
are also barriers to this support for research, including automated storage processes without 
explicit permission from parents (Botkin et al., 2012; Tarini et al., 2010) and distrust in 
authorities (Bombard et al., 2012), which have led to recent lawsuits challenging the storage of 
RBS (Bombard et al., 2012).  
In 2000 The American Academy of Pediatrics Newborn Screening Task Force set forth a 
broad agenda for state NBS systems. States were urged to develop and support information 
systems capable of tracking, among many things, long-term outcomes of children with special 
health care needs who were identified through the NBS program (Newborn Screening Authoring 
Committee, 2008). Contrasting the full control over information from privately released test 
results, information from NBS can be made widely available by entering such results into an 
information system, or registry. A medical registry has been defined as, “…an organized system 
for the collection, storage, retrieval, analysis, and dissemination of information on individual 
persons who have either a particular disease, a condition (e.g., a risk factor) that predisposes to 
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the occurrence of a health-related event, or prior exposure to substances (or circumstances) 
known or suspected to cause adverse health effects” (United States Department of Health & 
Human Services). Promising research results and possible clinical trials have brought a need for 
detailed NBS registries. NBS registries allow for collecting, viewing or searching data regarding 
patients’ phenotype and genotype profiles and other medical information that might benefit 
future studies and possibly inform new therapies (NCBDDD, 2004).  
Registries include both disease-specific and population-specific registries. Disease-
specific registries can act as surveillance programs to collect, view, and track both patient genetic 
data and health events over time to identify future therapeutic strategies and/or research studies 
(Botkin, Anderson, Staes & Longo, 2009). Disease-specific registries can also provide a forum 
for patient information exchange and support (Botkin et al., 2009). For example, the Cystic 
Fibrosis Patient Registry is a 40-year old registry containing more than 26,000 people with 
Cystic Fibrosis. Through this registry, researchers can study effective treatments, design clinical 
trials, and follow trends in patients’ health status (The Cystic Fibrosis Foundation, 2011). 
Broader, population-specific registries monitor segments of the population, tracking trends in 
health and healthcare. These registries, typically state- or county-wide, are used to report on gaps 
in healthcare and inform healthcare services policy. For example, KIDSNET is a Rhode Island 
Department of Health registry that follows the health and well-being of children up to age 18 
(Rhode Island Department of Health). Despite the existence of numerous NBS registries, there 
has been no research into whether parents’ NBS decision making is influenced by the amount of 




NBS is itself not a new concept. Since the 1960’s public health programs have been 
screening infants for serious diseases that have benefits to early diagnosis, namely an effective 
treatment. But with the expansion of optional NBS this area has become more complex; optional 
NBS is intermittently offered and, unlike mandatory NBS, provides no information with clinical 
implications. The decision to utilize optional NBS is left to the parents. While technological 
advances and optional NBS become more available and less expensive, there is a potential for 
increased optional NBS use. It is important to consider how these tests are being presented to 
decision makers before policies and universal guidelines are set, as the presentation and structure 
of optional NBS may influence utilization. Knowing whether such decisions are affected by 





The focus of this dissertation is to test how optional test decision making varies by 
features of test presentation and structure, as represented in optional newborn screening (NBS). I 
placed optional NBS decision making within the theoretical contexts of the Health Belief Model 
(HBM) and the Theory of Reasoned Action (TRA), with additional constructs informed by 
previous NBS research. The figure below is the theoretical framework I developed to connect 
existing work and guide future research (See Appendix A for a larger image). The framework is 
divided into three sections: modifying factors, pre-test factors (or influences that occur before 
NBS), and post-test factors (or influences that occur after NBS). Constructs not analyzed in the 
dissertation studies are shaded in grey.  




The modifying factors included in the theoretical framework above are informed by 
HBM. HBM describes modifying factors as the sociodemographics, personal experience/history 
and/or underlying knowledge that influence one’s health perceptions (Champion & Skinner, 
2008). The role of sociodemographics has been studied in nearly every testing context, except for 
NBS. Personal history has been a particularly influential modifying factor in screening decisions. 
In prenatal screening, personal experience with pregnancy, health-related matters, genetic 
conditions and disability affected interest in genetic screening (Archibald & McClaren, 2012; 
Etchegary et al., 2008). Although NBS has somewhat different implications from prenatal 
testing, they share similar influences of personal history and experience. Previous NBS research 
has shown that personal history, such as previous pregnancies and experience with genetic 
conditions, influences NBS decision making and whether parents feel that those decisions are 
informed (Davey et al., 2005; Lipstein et al., 2010; Nicholls & Southern, 2012).  
Pre-test Factors 
The pre-test factors in the theoretical framework are based largely on TRA (Fishbein & 
Ajzen, 1975), which has three main components: behavioral intention, attitudes, and subjective 
norms. A main tenet of TRA is that the main predictor of behavior is behavioral intention, which 
measures a person’s strength of intention to perform a specific behavior. Therefore in this 
framework, the predictor of optional NBS is optional NBS intention. TRA also asserts that 
behavioral intention is a function of the other two theoretical constructs, attitudes and subjective 




Turning to attitude constructs, the attitudes towards the optional NBS are influenced by 
attitudes towards NBS in general; though exact views may change from test to test, how one 
views NBS overall (important, unethical, etc.) informs the views about a specific NBS. The 
attitudes towards NBS in general are, in turn, likely informed by two constructs: knowledge 
about NBS and attitudes towards information in general. For example, there is the belief that the 
more information a person has, the better; this attitude would indicate support of NBS which 
gathers information about a child. Attitudes towards information have strong cognitive 
influences, such as cognitive style and information-seeking style. The need for cognition, or the 
tendency to engage in cognitive activity, is a type of cognitive style that has been shown to 
influence health beliefs and medical decision making (Cacioppo, Petty & Kao, 1984). 
Monitoring or blunting, or the tendency to seek or avoid threatening information (Miller, 1987), 
is one way to describe the way of seeking information. The Monitoring and Blunting Coping 
theory posits that people differ in their preference for information during an unfavorable event. 
This “difference” guides peoples’ attitudes towards information. The “monitors” are proactive 
and seek; they want to know all of the current information because it will alleviate stress and 
uncertainty. The “blunters” are passive and avoid information; they do not seek to alleviate 
uncertainty and prefer a state of ignorance if there is a risk of undesirable information/outcomes. 
Both of these types are seen in parents making NBS decisions, with some monitors actively 
seeking out information, and others only learning about NBS incidentally (Tluczek, Orland, Nick 
& Brown, 2009). In fact, one study found that parents classified as monitors requested 
information about the nature and purpose of NBS, as opposed to technical details or aspects 
relating to prevalence (Campbell & Ross, 2004). 
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The final element of TRA is subjective norms. This is an important factor in the 
theoretical framework, directly influencing NBS intention. Subjective norms are a consistent 
theme in NBS decision making; parents use a variety of sources of information and decision 
support in their NBS decisions. As developed in TRA, subjective norms are determined by one’s 
normative beliefs (whether a relevant person approves or disapproves of a behavior), weighted 
by his or her motivation to comply with that person (Montano & Kasprzyl, 2008). NBS programs 
provide information and decision support through pamphlets, pediatricians, midwives or nurses 
(Hargreaves et al., 2005; Munck et al., 2007; Parsons et al., 2006), but in addition to these 
medical sources parents rely on the experiences of their friends and family members (Davey et 
al,. 2005). Experiential knowledge is an important source of information for parents, which 
includes one’s own personal experience as well as the knowledge gained from others (Etchegary 
et al., 2008). In fact, much of parents’ NBS knowledge comes from hearing other parents at 
newborn visits (Detmar et al., 2007). It is not just NBS information receipt that is affected by 
family and friends; in a Welsh study of optional NBS utilization, the influence of family’s 
negative experience was the cause of higher refusal rate in a particular study area (Bradley, 
Parsons & Clarke, 1993). Subjective norms also indirectly influence intention with attitudes 
towards optional NBS as a mediator.  
The differential attention paid to the specific optional NBS v. mandatory NBS presented 
plays an important role. This describes the difference in attention a person pays to a single NBS 
test in the context of a mandatory NBS panel present, based on how that mandatory NBS panel is 
bundled. With a bundled mandatory NBS panel, there is a greater opportunity to focus on the 
single optional NBS decision. Mandatory NBS panels that are unbundled will directly affect the 
differential attention by presenting the mandatory tests individually, versus presenting 
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information as a group or a single unit. This differential attention directly influences optional 
NBS intention. Differential attention also affects the attitudes towards specific optional NBS, by 
pulling focus from, for example, the importance of the test.  
There are additional influences on both attention and differential attention, including 
perceived severity of the disease (a combination of perceived severity and perceived risk), and 
concern and knowledge about NBS. Perceived severity of the NBS for which the NBS is being 
done is constructed of both perceived risk and perceived severity, and is deeply influenced by 
one’s personal experience and familiarity with the disease (Davey et al., 2005). Depending on 
one’s perceived severity, he/she might pay less or more attention to the decision at hand. With 
experience and exposure to NBS one builds knowledge about the topic. Although studies have 
suggested that overall parents have a poor knowledge of NBS topics (Tluczek et al., 1992; 
Tluczek et al., 2005), increased knowledge is associated with increased attention to NBS.  
Post-test Factors 
In addition to the factors that occur before the NBS takes place, there are post-test factors 
that affect the decision to utilize optional NBS. In other words, what will happen after NBS is 
done influences whether someone has NBS in the first place. In the NBS timeline, after NBS is 
completed the next action step is the release of NBS results. The information from these results 
can be used for medical treatment or change in personal behavior, depending on the disorder and 
the treatment available, which are not universally proven to be effective but can be offered 
through optional NBS pilot programs.  
As shown in the theoretical framework, there is a feedback loop from releasing NBS 
results to NBS intention – knowing what will happen to the information may influence whether a 
person initially chooses NBS. Previous work has shown that parents have opinions about the use 
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of NBS information (Tabor, 2011); these opinions may also inform NBS intent. This feedback 
loop is moderated by a number of attitudes, however. First, one’s attitudes towards information; 
the theoretical constructs that contribute to these attitudes are cognitive style, such as need for 
cognition (Cacioppo et al., 1984), and information seeking, such as monitoring or blunting 
coping (Miller, 1987). For example, those who value having and sharing information will be 
more likely to utilize optional NBS if the results are to be disseminated widely.   
Attitudes towards altruism, privacy, medical mistrust, or mistrust in government are also 
influential moderators. There is a long history in the United States of medical mistrust, especially 
among racial minorities (Corbie-Smith, Thomas, Williams & Moody-Ayers, 2002; Corbie-
Smith, Thomas & St. George, 1999). One study found that trust in the medical community was 
central to the attitudes of the mothers considering NBS (Parsons et al., 2006). As outlined above, 
these three concepts have been shown to influence parents’ opinions towards NBS. For example, 
those who are altruistic and believe in helping society overall, do not have overwhelming privacy 
concerns about personal information, or do not mistrust the medical system, will be less likely to 
have their optional NBS decisions swayed by the way in which information is to be used.  
Theoretical Framework Summary 
The determinants of optional NBS decision making can be described in three different 
stages: 1) modifying factors such as sociodemographics, relevant personal experience/history 
(e.g. pregnancy), and underlying knowledge that influence one’s health perceptions; 2) pre-test 
factors such as NBS intention, informed largely by TRA as a function of attitudes and subjective 
norms, and differential attention; and 3) post-test factors that will occur after NBS is done, such 
as the release of NBS results. The feedback loop in the theoretical framework emphasizes how 
important knowing what will happen in future is to the initial decision. The individual 
19 
 
characteristics and personal attitudes included in the framework, such as attitudes towards 
altruism, privacy, and mistrust in the healthcare system, complete a NBS decision making 








An Exemplar: Duchenne Muscular Dystrophy 
The focus of this dissertation is to show that optional testing varies by features of test 
presentation and structure. Previous newborn screening (NBS) decision making research has 
focused mainly on the technical process of NBS and the psychosocial outcomes of NBS, but with 
the rise of optional NBS there is a need to study the specific determinants of these decisions. 
Detailed exploration of NBS decision making requires consideration of the details involved in a 
specific NBS context. This dissertation uses the exemplar of NBS for Duchenne muscular 
dystrophy (DMD). The larger research questions relevant in optional testing are specifically 
important in DMD NBS decision making. 
An Introduction to Duchenne Muscular Dystrophy   
DMD is a rare form of muscular dystrophy. It is a lethal X-linked genetic disorder for 
which a defective gene for a muscular protein causes rapid muscular degeneration. DMD can 
occur in people without a known family history (Kleigman, Behrman, Jenson & Stanton, 2007). 
Typically DMD occurs in boys; there is an incidence of 1 in 3,500 boys worldwide (Duchenne 
Muscular Dystrophy Research Fund). Although there are preliminary trials testing the use of 
steroids for DMD symptoms (ClinicalTrials.gov, 2011) no treatment is widely used that can alter 
the disease course of DMD. Therefore learning one’s DMD status does not improve clinical 
outcomes. Typical onset is between 3-5 years of age; symptoms include fatigue, learning 
difficulties, and muscle weakness (Ciafaloni et al., 2009). The muscle weakness is so progressive 
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that the majority of boys are in wheelchairs by the age of 10, have breathing difficulties and heart 
disease by age 20, and survival beyond 30 is rare (Kleigman et al., 2007; NCBDDD, 2004).   
Duchenne Muscular Dystrophy Newborn Screening 
In the 1970s, researchers developed a NBS blood test to identify cases of DMD 
(NCBDDD, 2004). The test was not introduced into the mandatory NBS panel because it 
provided no effective clinical advantages (Ross, 2006). Although DMD NBS is currently not 
available systematically, single pilot programs have offered the screening. Table 1 presents a 
brief history of pilot DMD NBS programs (Mendell et al., 2012), beginning in New Zealand 
(Drummond, 1979) and most recently in Ohio (Mendell et al., 2012). This most recent program 
in Ohio, the Statewide Newborn Screening for Duchenne Muscular Dystrophy program , offered 
voluntary DMD NBS from 2007-2011 in conjunction with The Research Institute at Nationwide 
Children’s Hospital, Cincinnati Children’s Hospital and the Ohio Department of Health, The 
University of Utah, and the Centers for Disease Control. DMD NBS was offered initially through 
a pilot study in several birthing hospitals in Columbus and Cincinnati, followed by an expansion 
to birthing hospitals throughout the state. This DMD NBS program was developed as a template 
to be expanded to a national voluntary screening program. DMD NBS utilization was high for all 
of the pilot DMD NBS programs (Parsons et al., 2006), with only one program still continually 




Table 1. A History of DMD NBS 
Year of 
Report 




New Zealand Drummond L.M. 10,000  
1982 Edinburgh, UK Skinner R., Emery A.E.H., 
Scheuerbrandt G., et al. 
2,336  
1986 West Germany Scheuerbrandt G., 
L€ovgren T., Mortier W. 
358,000  
1988 Manitoba, Canada Greenberg C.R., Jacobs 
H.K., Nylen E., et al. 
54,000  
1989 Lyon, France Plauchu H., Dorche C., 
Cordier M.P., et al. 
37,312 
1991 Western Pennsylvania, 
USA 
Naylor E.W. 49,000 
1993 Wales, UK Bradley D.M., Parsons 
E.P., Clarke A.J. 
34,219
a 
1998 Cyprus Drousiotou A., Ioannou P., 
Georgiou T., et al. 
30,014 
2006 Antwerp, Belgium Eyskens F., Philips E. 281,214
b
 
2012 Ohio, USA Mendell J.R., Shilling C., 
Leslie N.D., et al. 
30,547 
a
A second presentation in 2011 reported 335,045 newborns screened 
b
Only DMD NBS program continually active 
 
The arguments against DMD NBS are broad. In general, NBS must address the 
psychosocial, clinical and reproductive implications of genetic information for the child and the 
family (Ross, 2006); it is argued that optional NBS like DMD NBS, which expands information 
beyond the immediate care of the child, “muddles” the primary purpose of NBS (Bailey et al., 
2008). There is an overall desire “not to know” DMD NBS results (Parsons et al., 2006). Parents 
have reported that an DMD early diagnosis might lead to earlier stigmatization and 
discrimination (Dhondt, 2010), and diagnosing an illness without clinical treatments may disrupt 
the parent/newborn bonding relationship (Bailey Jr. et al., 2009; Goddard & Cardinal, 2004). 
Parents refusing DMD NBS have also cited the lack of treatment, no direct health benefits or 
economic value as their motive (Campbell & Ross, 2003; Parsons et al., 2006; Whitehead, 
Brown & Layton, 2010). In one study, 22% of parents refusing DMD NBS described no real 
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benefit of knowing and 14% cited no cure or proven treatment as their reason for declining 
(Cyrus, Street, Kable, Fernhoff & Quary, 2012). Finally, some parents are unsure of the 
implications of a positive NBS result (Ciske, Haavisto, Laxova, Rock & Farrell, 2001; Lang, 
McColley, Lester & Ross, 2011), although initial hyperawareness has not been associated with 
overuse of health care services (Lipstein, Perrin, Waisbren & Prosser, 2009). These existing 
drawbacks to DMD NBS have prevented it from becoming part of mandatory NBS. 
A CDC-sponsored workshop was held in 2004 to discuss not only the risks of, but also 
the benefits of DMD NBS. The workshop concluded that although there was inadequate 
evidence showing medical benefit from DMD NBS, early diagnosis might have other 
nonmedical advantages (NCBDDD, 2004). An earlier diagnosis could offer knowledge benefits 
by informing parents’ or other family members’ reproductive planning (Goddard & Cardinal, 
2004; Parsons et al., 2006) or an opportunity for immediate DMD education (Bailey Jr. et al., 
2009). Overall, more “time to prepare” has been cited widely as a benefit to DMD NBS, 
including relocating near treatment centers, home purchasing, financial planning, or employment 
opportunities (NCBDDD, 2004; Parsons et al., 2006; Pelias, 2006). As there are no universal 
early signs or symptoms that pediatricians use to recognize young children with DMD, so 
numerous testing and medical appointments may be necessary until final diagnosis, such as 
electromyography (EMG), muscle biopsy, or blood tests for CPK, an enzyme (Kleigman et al., 
2007). This investigative testing experience is known as the “diagnostic odyssey”, and can be a 
costly and anxiety-provoking one (Cyrus et al., 2012; Lipstein, Brinkman & Britto, 2012). Thus 





Exploring Emerging Questions 
The small body of NBS decision making research has been limited to psychosocial 
outcomes and parents’ attitudes towards mandatory NBS. Although it is known that partitioning 
NBS invitations decreases utilization (Moody & Choudhry, 2011), we do not know if related 
factors are potential influences on optional NBS decisions. Future optional NBS practices, which 
will only increase as technology advances, may be informed by knowing whether these decisions 
vary by features of the test presentation and structure. DMD offers an exemplar to study optional 
NBS questions because DMD testing occurs outside of the standardized processes of mandatory 






Introduction     
Little work has studied whether optional testing decisions vary by features of the test 
presentation or structural characteristics of the test. To start exploring these issues, I conducted a 
pilot study using DMD NBS as an exemplar of an optional test presented in the context of 
mandatory NBS. The study looked at this presentation characteristic as well as the test 
characteristic of test burden using experimentally-manipulated groups. Outcome variables 
included worry about the DMD NBS results and reported importance about: DMD NBS, DMD 
NBS results, and information from the DMD NBS results.  
Methods 
Study Participants 
Preliminary data collection used 2,085 adult participants in a larger, Internet-administered 
decision making study. Participants were recruited using Amazon.com’s Mechanical Turk 
(MTurk) interface. The average age of participants was 49 (SD = 16.3). Overall, participants 
were white (73.8%) and well-distributed in terms of education (22.5% attended some high school 
or attained a high school degree, 34.2% attended some college, and 43.3% attained a college 
degree or higher). Gender was evenly split between female (52.0%) and male (48.0%). 
Research Design 
Upon entering the study participants were assigned to one of three scenarios (see 
Appendix B for Preliminary Study Vignettes), each of which contained the following
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information: you and your partner have just given birth to a baby boy; DMD cannot be cured and 
the symptoms cannot be prevented; there is an optional test for screening newborn babies for 
DMD; the screening requires a blood sample but causes no long-term harm; the screening will 
not cost any money. The study explored the statistical differences in the three experimental 
groups that varied on three factors: bundling of the mandatory NBS panel presented with the 
optional DMD NBS, burden of DMD NBS, and the automatic release of DMD NBS information. 
Group 1: Participants in this group saw a mandatory NBS panel presented with optional 
DMD NBS that was bundled (the multiple NBS tests were presented as one package, “49”). The 
burden of the DMD NBS process, or the amount of logistical burden placed on the parent to 
complete the DMD NBS and the length of the NBS process, was non-existent; DMD NBS was 
done in the hospital with an existing blood sample so no additional actions were required. 
Finally, the information resulting from DMD NBS was to be released automatically.   
Group 2: Participants in this group saw a mandatory NBS panel that was unbundled (each of 
the 49 mandatory NBS in the panel were shown separately). The burden of DMD NBS was 
moderate (i.e. parents would have to send in a permission form for DMD NBS to be done on the 
existing blood sample), and the resulting information was not automatically released. 
Group 3: Participants in this group read about DMD NBS without the context of mandatory 
NBS, therefore the bundling factor was not manipulated. The DMD NBS burden was high—
parents would have to return to the hospital at a later time for DMD NBS. There was no specific 
mention of the DMD NBS results; therefore automatic release factor was not manipulated.  
Hypotheses 
H1) Participants given bundled DMD information (Group 1) will be more worried about 
DMD NBS results than participants given unbundled DMD information (Group 2).  
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This hypothesis tested the influence of bundling the mandatory NBS panel presentation. 
Based on the bundling literature, viewing the bundled (vs. the unbundled) mandatory NBS panel 
would allow participants to attend more to the single DMD NBS decision. This increased 
attention would lead to increased worry; participants who focused less on that single NBS 
decision would subsequently worry less about its specific results. 
H2) Participants given a high DMD NBS burden (Group 3) will report the DMD NBS, 
DMD NBS results, and the subsequent information as less important than participants given a 
low DMD NBS burden (Group 1).  
This hypothesis tested the influence of the time and effort required for DMD NBS on the 
value placed on DMD NBS and its results. With an increased burden people would see all facets 
of DMD NBS as less important and not worth the time and extra effort.  
Results 
The first hypothesis proposed that participants in Group 1, those shown a bundled 
mandatory NBS panel, would be more worried about DMD NBS results than participants in 
Group 2, those given an unbundled panel. As hypothesized, Groups 1 and 2 differed significantly 
on their reports of worry about the DMD NBS results (see Table 2). Though there were 
confounding factors, this result suggests that Group 2 gave less attention to DMD NBS 
compared to Group 1, and therefore focused less and worried less about that specific NBS result.  
Table 2. Group Differences in Reporting Worry about DMD NBS Results 
 Group 1 - % (N) 
Bundled 















The second hypothesis proposed the participants in Group 3 (high burden DMD NBS) 
would report the DMD NBS, DMD NBS results, and the subsequent information as less 
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important than participants in Group 1 (low burden DMD NBS). As proposed, there was a 
significant difference between Groups 1 and 3 in the ‘importance’ outcome variables (see Table 
3). It is difficult to tease apart these 2 groups by a specific factor, but knowing that for each of 
these variables Group 1 more often answered ‘more important’ may indicate that as the burden 
and length of the DMD NBS process increased, DMD NBS became less important and the 
information gleaned from the test was seen as not worth the time and extra effort.  
Most of the participants in Group 3, chose whether they would return to the hospital at an 
additional time for DMD NBS, reported that they would ‘definitely’ (32.9%) or ‘probably’ 
(41.7%) do so. Participants in Group 2, who chose whether they would mail in a permission form 
to have DMD NBS on an existing blood sample, responded similarly with 35.8% and 39.4% 
reporting they would ‘definitely’ or ‘probably’ do so, respectively (t=0.68, n.s.). Substantial 
proportions of participants strongly agreed that the DMD NBS results would help them prepare 
for the future (45.3%), affect whether they had more children (24.2%), and affect how they may 
treat their child (20.9%).     
Table 3. Group Differences in Reporting DMD NBS ‘Very Important’ 
 Group 1 -%(N) 
No burden 






DMD NBS ‘very important’ 48.71 (226) 31.94 (160) 32.79 (p<0.001) 
DMD NBS results ‘very important’ 58.48 (269) 48.40 (242) 9.86 (p<0.05) 
Information from DMD NBS 
results ‘very important’ 
69.63 (321) 56.49 (283) 22.69 (p<0.001) 
 
Implications for the Design of the Primary Research Studies 
The preliminary study showed group differences in worry, indicating that unbundling the 
mandatory NBS panels required participants to divide their attention and focus less on the DMD 
NBS decision. Group differences in the importance of DMD NBS, DMD NBS results, and the 
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resulting information indicated that as the burden and length of the DMD NBS process increases, 
the value of the test decreases. However the presence of multiple possible confounding factors 
suggests the need for a study with a multifactorial design. Therefore, these results support the 
notion that DMD NBS decisions do vary by features of presentation and structure, and advocate 







Introduction    
Optional NBS, such as DMD NBS, is often presented with mandatory NBS panels. The 
overarching research question of this dissertation is whether DMD NBS decisions vary by 
features of test presentation or structural characteristics of the test. Three studies separate studies 
addressed this question. Study 1 considered the influences on DMD NBS utilization given the 
context of mandatory NBS panels, specifically the notion of bundling. Researchers have 
supported the effect of bundling similar information, but none have studied how one decision is 
made in the context of bundled information. Study 1 also investigated the effect of subjective 
norms on the decision to utilize optional DMD NBS. NBS experiences of one’s families and 
friends are very influential in NBS decision making; optional NBS refusal rates have been 
attributed to family members’ negative experiences. In addition to their own experience and 
medical information, parents’ decisions may depend on subjective norms information. The 
conceptual model for Study 1 (Figure 2, below) describes specific hypothesized influences on the 
outcome variable DMD NBS intent. 
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Figure 2. Study 1 Conceptual Model 
 
I hypothesized that bundling the panel of mandatory NBS would predict DMD NBS 
intention through its manipulation of the differential attention paid to the mandatory NBS panels 
versus the single DMD NBS (H1). In the case of a panel with 49 mandatory NBS, I hypothesized 
that presenting DMD NBS next to 49 mandatory NBS listed one-by-one (unbundled) would 
highlight every NBS test and divide one’s attention, so participants would be more aware of (and 
possibly overwhelmed by) every NBS in the panel and be able to focus less on the single 
decision at hand than those seeing a bundled NBS panel (the statement “49 tests”). Participants 
viewing unbundled panels would be less likely to intend to utilize DMD NBS, compared to 
participants viewing bundled mandatory NBS panels. Essentially, the amount of attention that a 
person can give to DMD NBS would be affected by the way the mandatory NBS tests are shown 
in the panel, which may draw away attention.  
I also hypothesized that subjective norms would predict DMD NBS decision-making 
(H2). From the Theory of Reasoned Action ([TRA] Fishbein & Ajzen, 1975), subjective norms 
describe beliefs about what others want (normative beliefs) and how much people want to 
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comply with those desires (motivation to comply). Showing participants additional subjective 
norm information about other parents’ DMD NBS decisions (“most parents agree to DMD 
NBS”) would increase their intent to utilize DMD NBS. Finally, I hypothesized that attitudes 
about DMD NBS would predict DMD NBS intent, with more positive attitudes about DMD NBS 
associated with higher intent (H3).  
I developed hypotheses to test the influences of the study factors on the outcome variable 
attitudes about DMD NBS. Bundling would influence attitudes about DMD NBS by providing 
different contexts for focusing on DMD NBS (H4). Participants seeing unbundled mandatory 
NBS panels would report less positive attitudes about DMD NBS. Subjective norms would 
influence attitudes about DMD NBS (H5), as participants would have more positive attitudes as 
a reflection of the additional information about other parents’ high DMD NBS utilization. 
I set forth exploratory aims (E) to examine the associations between different attitudes in 
DMD NBS intention. The conceptual model presents links between attitudes about information 
in general, attitudes about NBS in general, and attitudes about DMD NBS. I tested this pathway 
of general to specific attitudes.  
Study Aims and Hypotheses 
Primary Aim: To examine the influences of the experimental factors on intended utilization of 
optional DMD NBS.  
H1: Participants seeing bundled mandatory NBS panels will report higher DMD NBS intention, 
compared to participants seeing unbundled mandatory NBS panels. 
H2: Participants viewing additional subjective norm information about parents’ DMD NBS use 




H3: Reporting more positive attitudes about DMD NBS will be associated with higher DMD 
NBS intention  
Secondary Aim: To examine the influences on attitudes about optional DMD NBS 
H4: Participants seeing bundled mandatory NBS panels will report more positive attitudes about 
DMD NBS, compared to participants seeing unbundled mandatory NBS panels. 
H5: Participants viewing additional subjective norm information about parents’ DMD NBS use 
will report more positive attitudes about DMD NBS, compared to participants not seeing such 
additional information.  
Exploratory Aim: To investigate the associations between different attitudes in DMD NBS 
intention 
Study Design  
The study had a 3x2 between-subjects experimental design: Bundling (bundled, 
unbundled, no panel) x subjective norm (specified, unspecified). Participants were randomly 
assigned to one of the six experimental conditions:  
        Subjective Norm 




 Bundled panel 1 4 
Bundling Unbundled panel 2 5 
 No panel 3 6 
 
Stemming from the literature and the conceptual model, bundling represented how the 
mandatory NBS tests are presented in a panel. By experimentally manipulating the information 
presentation in the study materials, participants were randomized into one of the three bundling 
groups: bundled, unbundled, or no panel. Participants in the bundled group saw a study brochure 
in which the mandatory NBS test were shown as a package (“49”). Participants in the unbundled 
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group saw a more detailed brochure in which each mandatory NBS test was shown separately. 
For those in the no panel group, mandatory NBS was not mentioned in the brochure. Participants 
were also randomized to a subjective norm group based on manipulation of study materials: 
norm specified or norm unspecified. Participants in the specified group read information about 
whether other parents are choosing the optional DMD NBS in addition to the basic information 
about NBS and DMD. They read the following sentence: “While you are talking, the nurse also 
tells you that most of the parents that she talked to about this test have agreed to have their baby 
screened for DMD.” Participants in the unspecified norm group did not read any additional 
information about other parents’ decisions.  
Methods         
Study Population and Participant Recruitment 
The study population was adult, Internet users living in the United States. An Internet 
survey facilitated the experimentally-manipulated conditions and ensured high internal validity 
of the randomized experiment by limiting selection bias. In a study with experimentally-
manipulated factors with a focus on variations across versions, my goal was to support internal 
validity. Participants were recruited using Amazon.com’s Mechanical Turk (MTurk) interface, 
which collects anonymous data for experimental studies. There were many advantages to using 
MTurk. First, MTurk survey respondents are often more representative of the U.S. population 
than in-person convenience samples (Berinsky, Huber & Lenz, 2011). Second, MTurk provides 
potential participants with the comfort of completing the survey at any time and any place, which 
increases response rates. Finally, MTurk recruitment is a rapid, cost-efficient method for 
recruiting participants. I followed established MTurk “tips” for recruitment, such as including the 
link to the survey in the HIT (human interface task), or survey request (Berinsky et al., 2011). 
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Participants were paid $0.75 for their participation directly through the MTurk system. This 
amount is consistent with current psychology lab practices on MTurk, which typically pay $0.10-
$1.00 for a 25-minute survey.  
Inclusion/Exclusion Criteria 
Inclusion criteria included: above the age of 21, United States resident, and the ability to 
complete a web-based survey. Age and United States residency were verified through MTurk 
user registration. The ability to complete a web-based survey was confirmed through the MTurk 
system, based on previous user performance. Similar to typical MTurk experimental studies, I 
enrolled only participants with a 90% “approval rate”, or a history of completing at least 90% of 
started surveys. Exclusion criteria included: under the age of 21, and less than a 90% approval 
rate. 
Data Collection 
The research program’s experimental study design lent itself to quantitative data 
collection. Qualitative data collection does not present the ability to cleanly manipulate multiple 
conditions involving visual distinctions, or assess immediate responses that reflect instinctive 
reactions. To collect such responses I programmed the surveys using the online survey platform 
Qualtrics.  
To begin each study, participants read a vignette that outlined a hypothetical situation in 
which they have a newborn (see Appendix C for Study 1 Vignettes). The vignette specified a 
male newborn, because most DMD NBS pilot programs are offered to male newborns only. This 
is because while DMD NBS identifies all male newborns with DMD, only some female carriers 
of DMD are detected and of those, full symptom expression of DMD is not common. Thus DMD 
NBS results are difficult to interpret in female newborns. Participants then read a brochure that 
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provided a detailed description of DMD, DMD NBS, DMD NBS results (see Appendix D for 
Study 1 Brochures). The format of information included in this brochure was modeled after the 
study brochure from the Statewide Newborn Screening for Duchenne Muscular Dystrophy pilot 
program in Ohio (Mendell et al., 2012; contact author for a side-by-side comparison of the study 
brochure and the Ohio pilot brochure). Both vignettes and brochures included manipulated study 
factors based on the experimental design, described above. After reading the vignettes and the 
brochures participants completed survey items. Items given to participants in Study 1 are 
described below; additional items for Studies 2 and 3 are described in those study chapters (see 
Appendix E for full items). 
Measures 
DMD NBS Utilization 
In the real world, the primary outcome of interest is utilization of DMD NBS. In the 
context of this hypothetical research study and informed by the TRA (Fishbein & Ajzen, 1975), I 
assessed intent to utilize DMD NBS as stated by participants. I used the following question: How 
likely do you think that it is that you will choose to have your baby tested for DMD?. I used a 
bidirectional, 4-point Likert scale with endpoints labeled Very Unlikely and Very Likely.  
Attitudes & Beliefs 
Following the conceptual model, I assessed respondents’ attitudes and beliefs 
surrounding three topics: 1) DMD NBS, 2) NBS in general, and 3) information in general (see 
Appendix E for full items). To assess attitudes about DMD NBS, I asked participants questions 
surrounding two topics: the importance of DMD NBS and the impact of DMD NBS. First, 
participants reported how important is…1) DMD NBS; 2) seeing the results of DMD NBS; and 
3) sharing the results of DMD NBS. Responses were on a 5-point Likert scale (Not at all 
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Important-Very Important). Then participants responded to the following five 
questions/statements about the impact of DMD NBS items, each on a 5-point Likert scale: 1) 
How much do you think you would worry about the results of your baby’s DMD test? (Not at 
all-Very Much); 2) The information from the DMD test may help me prepare for the future 
(Strongly Disagree-Strongly Agree); 3) The information from the DMD test would affect 
whether I have more children (Strongly Disagree-Strongly Agree); 4). The results from the DMD 
test may affect how I treat my child (Strongly Disagree-Strongly Agree); 5) My child would be 
treated differently by others if he is diagnosed with DMD (Strongly Disagree-Strongly Agree).  
To assess participants’ attitudes about NBS in general, they responded to the following 
two statements, both on a 5-point Likert scale from Strongly Disagree-Strongly Agree: 1) My 
child be treated differently by others if he has an incurable disease; 2) Having a child with an 
incurable disease would change how I might treat my child.  
Finally, I assessed participants’ attitudes about information in general with the following 
question on a 5-point Likert scale from Not at all Important-Very Important: How important is it 
that you have all the information available about your child?.  
Subjective Norms 
I measured participants’ own subjective norms about two topics: NBS in general and 
DMD NBS specifically. I used direct measures of subjective norms around NBS and DMD NBS 
specifically with the following two questions: 1) Do you think that most people agree or disagree 
that it is important for babies to be tested for as many genetic diseases as possible?; and 2) Do 
you think that most people agree or disagree with getting the DMD test?. I assessed the 
subjective norms on a scale scored from -3 to +3 (Agree – Disagree). There are established 
indirect measures of subjective norms based on the TRA’s normative beliefs and motivation to 
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comply, however I chose to use these direct measures. The indirect measures were not practical 
given the study methodology, because participants did not provide information about specific 
referent individuals in their lives with whose norms they want to comply. For example, an 
indirect measure of subjective norm would require a participant to name an important person 
(e.g. a mother) whose opinions/advice the participant wants to follow.  
Participant Demographics 
I collected the following demographics: gender (male; female), educational attainment 
(some high school; high school graduate/GED; some college or technical school; college degree; 
advanced degree), marital status (married/partnered; not married/partnered), and household 
income. The response options for household income were based on the National Health 
Interview Survey ([NHIS]; Centers for Disease Control and Prevention [CDC]) response options 
calculated by adjusted poverty level based on family size: less than $14,500; $14,500-less than 
$35,000; $35,000-less than $50,000; $50,000-less than $75,000; $75,000-less than $100,000; 
$100,000 and over. Participants reported their race: White; African American/Black; Native 
Hawaiian and Other Pacific Islander; Asian; American Indian/Alaska Native. The response 
options for race were also based on the NHIS (CDC). Participants entered their age in an open-
ended question, which was later categorized into: 21-35, 36 and above, missing. I chose 35 as the 
cut-off point because pregnancy at age 35 is the typical point at which additional prenatal 
screening for abnormalities has been recommended. I created a separate missing category due to 
the high proportion of non-responses.  
To measure experiential knowledge, participants reported their experience working in the 
health field or research field (current; previous; never) and the following relevant histories: 
number of pregnancies (open), previous pregnancy complications (yes; no; don’t know), 
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previous prenatal screening (yes; no; don’t know), number of children (open), previous NBS 
(yes; no; don’t know), child health history (an acute illness; a chronic illness; a genetic illness; 
no; do not know), and familiarity with DMD (I know someone diagnosed with DMD; I know 
someone diagnosed with another genetic disorder; no; do not know). 
Data Analyses 
The primary aim was to examine the influences on intended utilization of optional DMD 
NBS. To test the main effects of mandatory NBS panel bundling and subjective norms, I used 
ANOVA to compare the mean intended DMD NBS utilization scores across the experimental 
groups and Bonferroni post-hoc pairwise comparisons to see which means were different from 
each other. Then I used ordered logistic regressions to analyze whether bundling, subjective 
norms, and the interaction of the two predicted choice. I created two regression models: the 
baseline model included the predictor variables; the secondary regression model added 
participant demographics. To test whether attitudes towards DMD NBS predicted DMD NBS 
intent I used ordered logistic regressions. I created two regression models: the baseline 
regression model included attitudes about the importance of DMD NBS; the secondary model 
added attitudes about the impact of DMD NBS. These models controlled for age, race, gender, 
marital/partnered status, previous pregnancy, level of education, and household income. The 
secondary aim was to test the influences of the study experimental factors on attitudes about 
DMD NBS and participants’ own subjective norms. I used ANOVA and t-tests to test the effects 
of bundling and subjective norms, respectively.  
Sample Size  
The primary outcome variable was DMD NBS utilization, measured by intent to utilize. 
To calculate sample size I looked at the variance in survey responses observed in the preliminary 
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dataset. Specifically, I looked at the two most relevant test groups (bundled and unbundled) and 
compared the mean values (2.53, 2.28) and standard deviations (1.29, 1.29) of the 5-point Likert 
scale item worry about the result of DMD NBS, which was associated with intent to utilize DMD 
NBS. Based on these numbers and using 80% power and significance of 0.05, N=425 per cell, or 
a total sample size of N=2,250 was needed.   
Results 
A total of 3,215 surveys were completed. 224 surveys were excluded for participants 
reporting an age less than 21 per the exclusion criteria, resulting in a final N of Study 1 of 2,991. 
Participants were predominately white (79.9%), male (52.4%), unmarried/unpartnered (60.1%), 
and had no children (64.5%). The average age was 29.3 (range 21-82). Participants mostly had a 
college degree (42.1%) and had a household income of $14,500 to under $35,000 (26.0%). See 




Table 4. Study 1 Participant Characteristics (N=2,991)
a
 
 % (N) 
Age (range, mean) 
21-35 









































$14.5 to <$35k 
$35k to <$50k 
$50k to <$75k 
$75k - <$100k 


















Number of Children 
0 
1 






N varies due missing data. Percentage of 
missing data < 0.50% for all variables 









The primary aim was to test the influences on intended utilization of optional DMD NBS. 
First I looked at the effect of bundling the mandatory NBS panels. There was a significant 
difference across groups in the mean scores for likelihood of choosing DMD NBS (F=5.79, 
p=0.003, See Table 5), but post-hoc analyses revealed no significant difference between the 
bundled and unbundled groups. Instead, DMD NBS intent scores for participants in the no panel 
group were significantly lower than the other two groups. From the regression models, the 
bundling of the mandatory NBS panel did not influence the DMD NBS decision as hypothesized. 
However people given information about DMD NBS with either a bundled or unbundled 
mandatory NBS panel were more likely to choose DMD NBS, compared to those given 
information without the context of a mandatory NBS panel (OR=1.44, CI=1.10, 1.89, p<0.01; 
OR=1.34, CI=1.03, 1.74, p<0.05, respectively, see Table 6, Model 1). These findings remained 
significant after controlling for demographic characteristics (Table 6, Model 2). 







 No Panel Bundled Unbundled Total Mean (SD)
b 
No 3.50 3.61 3.60 3.57 (0.77) 
Yes 3.46 3.53 3.58 3.53 (0.78) 
Total Mean (SD)
c 
3.48 (0.81) 3.57 (0.77) 3.59 (0.74)  
a
Mean (SD); 1=very unlikely, 4=very likely 
b
Difference between means across subjective norms groups t=1.35, p=0.18 
c
Difference between means across panel bundling groups F=5.79, p=0.003 
 
There was no significant difference in the means of DMD NBS intent between the two 
subjective norms groups (Table 5), nor was choosing DMD NBS predicted by the presentation of 
additional subjective norms information (OR=0.90, CI=0.70, 1.15, n.s.; See Table 6, Model 1). 
Although there was a main effect of bundling, there were no interaction effects between 
mandatory NBS panel bundling and subjective norms. Certain demographic characteristics 
predicted likelihood of choosing DMD NBS (Table 6, Model 2). Female participants were more 
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likely than their male counterparts to choose DMD NBS (OR=1.19, CI=1.00, 1.42, p<0.05). 
African American participants (compared to white participants) and participants with a high 
school degree or less (compared to their more educated counterparts with a college or advanced 
degree) were less likely to choose DMD NBS (OR=0.63, CI=0.44, 0.89, p<0.01; OR=0.75, 
CI=0.56, 0.99, p<0.05, respectively). Pregnancy history played an important role; participants 
with a previous pregnancy (either their own or their partner’s) were less likely to choose DMD 




Table 6. Study 1 Test Characteristic and Demographic Predictors of Choosing DMD NBS 
 MODEL 1 (N=2,991) 
Baseline Regression 











1.44 (1.10, 1.89)** 





1.35 (1.01, 1.81)* 
Subjective norm  




0.90 (0.70, 1.15) 
 
Reference 
0.89 (0.68, 1.18) 
Interaction 
No panel x norm 
Bundled x norm 
Unbundled x norm 
 
Reference 
0.89 (0.61, 1.30) 
1.06 (0.73, 1.53) 
 
Reference 
0.87 (0.57, 1.31) 
1.04 (0.70, 1.56) 
Age 
21-35 















0.63 (0.44, 0.89)** 
1.37 (0.98, 1.90) 
























0.65 (0.53, 0.80)*** 
Education Level 
College/Adv degree 
Some college/Tech  





1.12 (0.94, 1.35) 
0.75 (0.56, 0.99)* 
Income 
<$35k 
$35k to <$75k 





1.15 (0.95, 1.40) 
1.13 (0.89, 1.44) 





The likelihood of choosing DMD NBS was also predicted by attitudes about DMD NBS 
(Table 7). Model 1 explored attitudes about DMD NBS importance; all three were significant 
predictors. Participants who reported higher importance of DMD NBS were over three times as 
likely to choose DMD NBS than those who reported lower importance (OR=3.73, CI=3.24, 4.29, 
p<0.001). Similarly, higher reported importance of seeing the DMD NBS results was associated 
with increased likelihood of choosing DMD NBS (OR=2.36, CI=2.06, 2.70, p<0.001). The third 
“importance” measure, how important it is to share the DMD NBS results with others, was also 
significant, but participants reporting high importance for sharing results (vs. low importance) 
were less likely to choose DMD NBS (OR=0.87, CI=0.80, 0.94, p<0.01). Model 1 controlled for 
bundling, subjective norms, and the demographic characteristics included in Table 6 Model 2. 
African American race (p<0.05), previous pregnancy (p<0.001), high school education or less 
(p<0.001) and a bundled mandatory NBS panel (p<0.01) remained significant factors.  
The likelihood of choosing DMD NBS was also predicted by two attitudes about the 
impact of DMD NBS (Table 7, Model 2). Participants who reported that the information from 
DMD NBS may help prepare for the future were over two times as likely to choose DMD NBS 
(OR=2.26, CI=1.94, 2.63, p<0.001), and participants reporting worry about the DMD NBS 
results were less likely to choose DMD NBS (OR=0.67, CI=0.60, 0.73, p<0.001). The impact of 
DMD NBS results on reproductive planning, how you might treat your child, and how others 
might treat your child were not significant predictors. Adding these additional attitude measures 
did not change the significance of reported importance of DMD NBS (OR=3.56, CI=3.05, 4.15, 
p<0.001) or seeing the DMD NBS results (OR=2.14, CI=1.86, 2.47, p<0.001), however, 
reporting importance of sharing the DMD NBS results was no longer a significant predictor of 
DMD NBS (OR=0.95, CI=0.87, 1.04, n.s.).  
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Turning to participants’ own subjective norms (Table 7, Model 3), subjective norms 
around NBS in general and subjective norms around DMD specifically were not equally as 
important. There was no association between DMD NBS intent and subjective norms around 
NBS in general, but participants reporting higher subjective norms around DMD NBS 
specifically were more likely to choose DMD NBS (OR=1.26, CI=1.14, 1.41, p<0.001). All three 
regression models controlled for the main effects, interaction effects, and demographic 
characteristics in Table 6 Model 2.  
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+ Attitudes about the 





+ Subjective norms 
 
 
Mean (SD) OR (95% CI) OR (95% CI) OR (95% CI) 
Importance of DMD NBS 4.07 (1.05) 3.73 (3.24, 4.29)*** 3.56 (3.05, 4.15)*** 3.18 (2.71, 3.72)*** 
Importance of seeing the 
DMD NBS results 
4.42 (0.97) 2.36 (2.06, 2.70)*** 2.14 (1.86, 2.47)*** 2.10 (1.82, 2.42)*** 
Importance of sharing the 
DMD NBS results 
2.64 (1.33) 0.87 (0.80, 0.94)** 0.95 (0.87, 1.04) 0.91 (0.83, 1.00)* 




--- 0.67 (0.60, 0.73)*** 0.62 (0.56, 0.69)*** 
The results may help 
prepare you for the future 
4.40 (0.80) 
 
--- 2.26 (1.94, 2.63)*** 2.02 (1.72, 2.36)*** 
The results may affect if 
you have more children 
3.20 (1.20) 
 
--- 0.99 (0.90, 1.09) 0.98 (0.89, 1.08) 
The results may affect how 
you might treat your child 
2.91 (1.34) 
 
--- 0.96 (0.88, 1.05) 0.96 (0.88, 1.05) 
The results may affect how 
others treat your child 
3.63 (1.02) 
 
--- 1.08 (0.96, 1.22) 1.07 (0.95, 1.21) 
Subjective norms around 
NBS in general 
5.48 (1.56) --- --- 1.10 (0.99, 1.22)  
Subjective norms around 
DMD NBS specifically 
5.55 (1.56) --- --- 1.26 (1.14, 1.41)*** 
a
Models controlled for all factors in Table 3, Model 2 
b
Significant control factors: African American race (p<0.05), previous pregnancy (p<0.01), high school education 
or less (p<0.001), bundled panel (p<0.01) and unbundled (p<0.05) panel  
c
Significant control factors: Age (p<0.05), previous pregnancy (p<0.01), HS education or less (p<0.001), bundled 
panel (p<0.01) and unbundled panel (p<0.05) 
d






The secondary aim was to look at the effect of the manipulated study conditions on DMD 
NBS attitudes. There were effects of mandatory NBS panel bundling (Table 8). Participants who 
read about DMD NBS without the context of a mandatory NBS panel reported DMD NBS to be 
less important and reported that they would worry more about DMD NBS results than those who 
saw either a bundled or unbundled panel (F=3.40, p<0.05; F=3.48, p<0.05, respectively). 
Participants’ own subjective norms (i.e. reporting how they think what most other people 
believe) were associated with bundling; those who viewed DMD NBS without the context of a 
mandatory NBS panel (either unbundled or bundled) reported weaker norms around the 
endorsement of both NBS in general and DMD NBS specifically than those viewing either an 




Table 8. Attitudes about DMD NBS, by Mandatory NBS Panel Bundling  
 Panel Bundling  








Importance of DMD 
NBS 
4.08 (1.09) 4.12 (1.00) 4.00 (1.05) 3.40* 
Importance of seeing 
the DMD NBS results 
4.42 (0.98) 4.46 (0.90) 4.38 (1.01) 1.80 
Importance of sharing 
the DMD NBS results 
2.68 (1.34) 2.62 (1.31) 2.61 (1.35) 0.74 
Worry about the DMD 
NBS results 
3.42 (1.25) 3.45 (1.20) 3.56 (1.20) 3.48* 
The results may help 
prepare you for the 
future 
4.39 (0.83) 4.41 (0.79) 4.39 (0.77) 0.21 
The results may affect 
if you have more 
children 
3.21 (1.22) 3.19 (1.19) 3.20 (1.21) 0.08 
The results may affect 
how you might treat 
your child 
2.89 (1.35) 2.93 (1.34) 2.92 (1.35) 0.24 
The results may affect 
how others treat your 
child 
3.58 (1.06) 3.64 (0.96) 3.66 (1.02) 1.73 
Subjective norms 
around NBS in general 
5.64 (1.52) 5.71 (1.49) 5.30 (1.63) 20.01** 
Subjective norms 
around DMD NBS 
5.53 (1.57) 5.60 (1.54) 5.31 (1.56) 9.29** 
*p<0.05, **p<0.01 
 
There was a group difference in only one attitude measure when looking at the subjective 
norms study condition (Table 9). Participants who saw additional subjective norm information 
about how most other parents choose DMD NBS reported that the DMD NBS results would have 
less of an effect on whether they might have more children than those who did not see additional 




Table 9. Attitudes about DMD NBS, by Subjective Norm  







Importance of DMD 
NBS 
4.05 (1.05) 4.08 (1.05) -0.72 
Importance of seeing 
the DMD NBS results 
4.42 (0.96) 4.42 (0.98)  -0.20 
Importance of sharing 
the DMD NBS results 
2.62 (1.33) 2.66 (1.34)  -0.90 
Worry about the DMD 
NBS results 
3.47 (0.03) 3.47 (0.03) 0.01 
The results may help 
prepare you for the 
future 
4.38 (0.80) 4.42 (0.80) 1.45 
The results may affect 
if you have more 
children 
3.14 (1.21) 3.27 (1.20) 3.10** 
The results may affect 
how you might treat 
your child 
2.88 (1.35) 2.94 (1.34) 1.28 
The results may affect 
how others treat your 
child 
3.62 (1.00) 3.63 (1.03) 0.38 
Subjective norms 
around NBS in general 
5.56 (1.55) 5.54 (1.56)  -0.24 
Subjective norms 
around DMD NBS 




The primary aim was to test the influences of the study factors on intended utilization of 
optional DMD NBS. The data did not support my original hypothesis that participants viewing 
bundled mandatory NBS panels would report higher DMD NBS intention compared to 
participants seeing unbundled mandatory NBS panels. This null finding was possibly due to a 
ceiling effect, as the vast majority of participants chose DMD NBS in this study. Despite the null 
finding, further research on the effects of bundling is needed. For example, the effect of bundling 
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might be more significant when measured in a clinic during actual decision making, in concert 
with the stressors of a clinical environment. However I did find that participants given DMD 
NBS information in the context of either a bundled or unbundled mandatory NBS panel were 
more likely to choose DMD NBS than those not shown a mandatory NBS panel at all. This 
finding indicates that when participants were not given the context of broader mandatory NBS in 
which to place a specific optional NBS, they were more hesitant to choose testing.  
Participants viewing additional subjective norm information about parents’ DMD NBS 
utilization did not report higher DMD NBS intention compared to participants not seeing such 
additional information, contrary to my original hypothesis. However, additional results showed 
that participants’ own subjective norm (what important people in their lives think) towards DMD 
NBS specifically was a significant predictor of intent. Together these results lend support to 
TRA; it is the norms of identified people in some one’s life that are influential, while the overall 
norms of unidentified people akin to the participants, whom they do not know, are not influential 
in decision making. These findings correspond with previous research which has asserted that 
family members’ and friends’ experiences and opinions are very influential in NBS decision 
making (Bradley et al., 1993; Davey et al., 2005). Given the strength of subjective norms when 
based on specific people the decision maker knows and not a nebulous similar group, developers 
of health decision materials should be careful not to overemphasize the benefit of language such 
as “people like you” and instead focus on the important people specific to a decision maker. 
The likelihood of choosing DMD NBS was also predicted by attitudes about DMD NBS, 
following previous research about parents’ interest in NBS. Participants reporting higher 
importance of DMD NBS in general and seeing the DMD NBS results were more likely to 
choose DMD NBS. However, participants reporting higher importance of sharing the DMD NBS 
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results were less likely to choose DMD NBS. One possible explanation for this finding is that 
participants may value the concept of sharing results, but not want to share results that are 
relevant to them specifically (e.g. their child’s NBS results). Instead of facing that cognitive 
dissonance, they would reject the testing. Similar to previous research, participants reporting that 
the information from DMD NBS may help prepare for the future were more likely to choose 
DMD NBS (Parsons et al., 2006; Pelias, 2006), and participants reporting increased worry about 
the DMD NBS results were less likely to choose DMD NBS (DeLuca, Kearney, Norton & 
Arnold, 2011; Waisbren et al., 2003). Future NBS programs should address parental worry; it is 
possible that heightened worry is one element preventing an otherwise desired optional NBS. 
Unlike previous research (Dhondt, 2010; Parsons et al., 2006), participants’ reporting that the 
information from DMD NBS may help future reproductive choices or lead to discrimination did 
not predict DMD NBS choice.  
Mandatory NBS panel bundling influenced participants’ attitudes just as it influenced 
DMD NBS intention. Participants who read about DMD NBS without the context of mandatory 
NBS (compared to participants who saw either a bundled or unbundled panel) found DMD NBS 
less appealing overall. They reported DMD NBS to be less important, that they would worry 
more about DMD NBS results, and that there were weaker norms around the endorsement of 
both NBS in general and DMD NBS specifically. Although presenting additional subjective 
norm information did not affect DMD NBS intent, it did influence reproductive planning. 
Participants who saw additional information about most parents agreeing to DMD NBS reported 
that the DMD NBS results would have less of an effect on whether they had more children. This 
finding is logical; presenting the norm that parents engage in DMD NBS would alleviate the 
inclination to delay childbirth in order to avoid DMD NBS. 
53 
 
Increased likelihood of DMD NBS intent was predicted by demographic characteristics. 
Female participants were more likely to choose DMD NBS (vs. male), while participants who 
were African American (vs. white), had a previous pregnancy (vs. no previous pregnancy), and 
had a high school degree or less (compared to their more educated counterparts with a college or 
advanced degree) were less likely to choose DMD NBS. The race/ethnic result may reflect the 
long history of medical mistrust, especially among racial minorities (Corbie-Smith et al., 2002; 
Corbie-Smith et al., 1999).  
Overall, these results communicate that viewing DMD NBS information without the 
larger context of mandatory NBS plays an important role in decision making. The provision of 
this context (regardless of a bundled or unbundled format) affected DMD NBS intent as well as 
attitudes about DMD NBS. Offering additional subjective norm information about parents akin 
to the participants did not have an effect, but participants’ own subjective norms about people 
important in their own lives had a very strong one. Future optional NBS programs should be 
careful to sufficiently present the testing information within an appropriate context while 
recognizing that decision makers may not relate to the choices of unfamiliar, albeit similar, 






After NBS is complete, the information from the results is released. How, and to whom, 
this information is released is a test structure feature that can vary from test to test. While 
previous research has studied parental preferences for the way in which NBS information is 
released and its effect on psychosocial outcomes, it is unknown whether advance knowledge 
about how the NBS information will be released effects outcomes of interest. Study 2 considered 
this possible determinant for the initial decision to utilize DMD NBS.  




The conceptual model for Study 2 (Figure 3, above) describes hypothesized influences on 
DMD NBS intention. In the DMD NBS process, shown in the conceptual model, there are two 
main action steps: 1. utilizing the test; 2. releasing the results of the test. I hypothesized that 
when faced with the DMD NBS decision, knowing how the results are to be released would 
influence the decision-making process; a feedback loop would exist from DMD NBS release to 
the DMD NBS intent (H1).  
Additionally, the release of DMD NBS results could interact with related personal 
beliefs, such as preferences for where personal information should be kept and whether the 
institutions that collect information are trustworthy. Therefore I hypothesized the relationship 
between DMD NBS release and DMD NBS intent would be moderated by attitudes towards 
altruism, need for privacy, medical mistrust, and government mistrust (H1a). A high need for 
privacy, medical mistrust, or government mistrust would mitigate an effect of increased DMD 
NBS results release on DMD NBS intention, whereas a high value on altruism may strengthen 
that relationship, as they consider the sharing of DMD NBS results as an altruistic way to 
contribute to future medical treatments and/or cures. Main effects would parallel these 
hypotheses: participants with high need for privacy, medical mistrust, or government mistrust 
would have less DMD NBS intent.  
I hypothesized that participant’s subjective norms associated with NBS in general and 
DMD NBS specifically would be associated with DMD NBS intention (H2). Reporting more 
positive subjective norms will be associated with higher likelihood of DMD NBS intent. Finally, 
I hypothesized that attitudes about DMD NBS would influence DMD NBS intent, with more 




Study Aims and Hypotheses 
Primary Aim: To examine influences of the study experimental factors on intended DMD NBS 
utilization.  
H1: As the DMD NBS results are released to more people in addition to the parents, participants 
will be less likely to choose DMD NBS.  
a) This relationship is moderated by attitudes towards altruism, need for privacy, medical 
mistrust, and mistrust in government, such that the hypothesized relationship will be 
mitigated for those with high altruism and attenuated for those with high need for 
privacy, high medical mistrust, and high government mistrust.  
H2: Reporting more positive subjective norms around NBS in general and DMD NBS 
specifically will be associated with higher DMD NBS intention 
H3: Reporting more positive attitudes about DMD NBS will be associated with higher DMD 
NBS intention 
Study Design  
The study was a randomized survey experiment using a single factor with 5 experimental 
groups, varying by how the information from DMD NBS is released. Participants were randomly 













1 2 3 4 5 
 
Release of results is what would happen to the information from the DMD NBS results. 
Participants were randomized into one of five groups that varied the study brochure’s 
information about the type of results release: private release; EHR; research biobank; DMD 
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registry; and general registry. Participants in the private release group read that the DMD NBS 
results would be returned to the family by a private NBS company, and no others would have 
access to the results unless given permission. Participants in the EHR group read that the DMD 
NBS results would be viewable to the medical professionals associated with the child, both 
present and future, in addition to the family having access to the results. Participants in the 
research biobank condition read that residual blood specimens from the DMD NBS results would 
be stored in a hospital biobank to be used for future research, in addition to the family having 
access to the results. There were two groups that were presented with registry scenarios. The first 
read about a DMD-specific national registry in which the DMD NBS result information would 
be entered, similar to an existing Duchenne Connect patient registry with over 2,500 registrants 
from 100 countries (Duchenne Analytics, 2011). This registry would have implications for future 
DMD treatment and testing options, and therefore individual benefit for those diagnosed with 
DMD. The second group read about a general national registry that follows overall trends in 
children’s health. The DMD NBS result information would be entered in this registry, but it 
would have no direct implications for DMD treatment or individual benefits for those enrolled 
regarding DMD.  
Methods 
Summary of Methodology 
 The methodology for Study 2 is similar to that for Study 1. Briefly, participants above the 
age of 21, living in the United States and able to complete a web-based survey were paid $0.75 
to complete an MTurk-administered Internet study. To begin each study, participants read a 
vignette that outlined a hypothetical situation in which they have a newborn son and then a 
brochure that provided a detailed description of DMD, DMD NBS, and DMD NBS results. The 
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basic information about the hypothetical scenario, DMD and DMD NBS remained the same as in 
the Study 1 brochures. However, the Study 2 brochure manipulated the information about the 
release of the DMD NBS results based on the experimental design (see Appendix F for Study 2 
vignettes and Appendix G for Study 2 brochures). Then, as in Study 1, participants completed 
survey items that measured DMD NBS intention, attitudes and beliefs, subjective norms, and 
demographics (see Study 1 for a detailed methods; see Appendix E for complete survey items). 
Additional Survey Measures for Study 2 
Study 2 focused on the release of results as a predictor of DMD NBS intent. As described 
in the conceptual model, I hypothesized that this relationship is moderated by beliefs related to 
how personal information should be used and trust. Four attitudes that capture such beliefs are: 
altruism, need for privacy, medical mistrust, and government mistrust. Thus participants in Study 
2 completed additional survey items to assess these constructs.  
I measured altruism using eight “safe” altruism items from the 14-item altruism scale 
adapted by Homant (2010). I excluded the six “risky” altruism items, which include behavior 
such as giving a ride to a stranger or making change for a stranger, as they were not relevant to 
the study. The “safe” altruism items include donating to a charity, volunteering, and simple, 
everyday courtesies that might indicate a desire to help others through varying degrees of 
contribution to the larger medical field (see Appendix E for a full description of items). 
Participants reported how frequently they committed these acts on a 5-point Likert scale from 
Never to Very Often. A total altruism score was calculated by averaging each item, with higher 
levels indicating higher altruism.  
To measure need for privacy I turned to the 15-item Concern for Information Privacy 
instrument ([CFIP]; Smith, Milberg & Burke, 1996), which was designed to measure levels of 
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concern about information privacy practices with respect to data collection, data errors, improper 
access of data, and unauthorized secondary use of data. I used the 4-item data collection subscale 
that focuses on sharing personal information, and assigns an overall need for privacy score by 
averaging each item on 7-point Likert scale from Strongly Disagree to Strongly Agree, with 
higher levels indicating a higher need for privacy. See Appendix E for a full description of items. 
I measured medical mistrust with the 10-item Health Care System Distrust Scale (Rose, 
Peters, Shea & Armstrong, 2004), which asks participants their agreement with statements about 
health care system mistakes, testing/experiments without consent, access to medical records, and 
quality of care (see Appendix E for full description of items) on a 5-point Likert scale from 
Strongly Disagree to Strongly Agree. An overall medical mistrust score was calculated by 
averaging each item, with higher levels indicating higher medical mistrust.  
To measure government mistrust I used a 6-item validated scale from Peters & Slovic 
(1996) that measures trust in the government/public officials resolving problems, withholding 
information, and contributing to problems on a 4-point Likert scale from Strongly Agree to 
Strongly Disagree (see Appendix E for a full description of items). An overall government 
mistrust score was calculated by averaging each item, with higher levels indicating higher 
government mistrust. 
Data Analyses 
The analysis plan followed the same principles and methods as in Study 1. To test the 
effects of release of DMD NBS results I used ANOVA and Bonferroni post-hoc pairwise 
comparisons to compare the mean intended DMD NBS intent scores across the experimental 
groups and ordered logistic regressions to analyze whether results release predicted choice, using 
private release as the reference group. I created three regression models: the baseline model 
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included the results release manipulation; the secondary model added altruism, need for privacy, 
medical mistrust and government mistrust; the tertiary model added participant demographics. I 
used ordered logistic regressions for each moderating variable to test for interactions as well as 
main effects. To test whether participants’ attitudes towards DMD NBS and their own subjective 
norms predicted DMD NBS choice I used logistic regressions. I created three models: the first 
model included attitudes about the importance of DMD NBS; the secondary model added 
attitudes about the impact of DMD NBS; the tertiary model added participants’ subjective norms. 
All regressions controlled for age, race, gender, marital/partnered status, previous pregnancy, 
level of education, and household income. 
Sample Size 
My primary outcome variable was intent to utilize DMD NBS. Because the Study 2 
factors were not explicitly addressed in the preliminary dataset, I looked at the most relevant 
factor: reporting the information from DMD NBS as being important information. I used the two 
groups of people who reported the information being important and not important and compared 
the mean values and standard deviations of the 5-point Likert scale item likelihood to choose 
DMD NBS. Using 80% power and significance of 0.05, N=310 per cell, or a total sample size of 
N=1,550 was needed.   
Results 
A total of 1,604 surveys were completed. Similar to Study 1, participants were 
predominately white (80.5%), male (60.5%), unmarried/unpartnered (66.3%), and had no 
children (75.8%). The average age was 29.5 (range 21-74). Participants mostly had a college 
degree (41.0%) and had a household income of $14,500 to under $35,000 (23.5%). See Table 10 
for full participant characteristics. 
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 % (N) 
Age (range, mean) 
21-35 








































$14.5 to <$35k 
$35k to <$50k 
$50k to <$75k 
$75k - <$100k 


















Number of Children 
0 
1 






N varies due to missing data. Missing data 
< 1.0% for all variables except age (10.0%) 
b
Own or partner’s pregnancy  
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Looking at all five groups of results release, I chose to use EHR as the reference group; 
participants in this group had the highest proportion of DMD NBS intent (Table 11). Although 
there was no overall statistical significant difference across all five groups (F=1.65, p=0.16, see 
Table 11), post hoc analyses revealed a significant difference between the EHR release group 
and the biobank release group (chi
2
=5.51, p=0.02). Using this reference group, there was a main 
effect of results release for one comparison (Table 12, Model 1). Participants given DMD NBS 
with a biobank release were less likely to choose DMD NBS than those given DMD NBS with 
the EHR release (OR=0.72, CI=0.52, 0.99, p<0.05). This finding remained significant after 
adding attitudes and participant demographics (Table 12, Models 2 and 3). However no other 
results release groups were significant.  








3.52 (0.80) 3.53 (0.81) 3.39 (0.92) 3.44 (0.86) 3.50 (0.85) 
a
Mean (SD); 1=very unlikely, 4=very likely 
Difference between means across results release groups F=1.65, p=0.16 
 
Medical mistrust played a significant role in DMD NBS choice (see Table 12, Model 2). 
Participants reporting high medical mistrust were significantly less likely to choose DMD NBS 
than those reporting low mistrust (OR=0.56, CI=0.46, 0.69, p<0.001). Government mistrust was 
also a significant predictor; overall, participants reporting high government mistrust were 
significantly more likely to choose DMD NBS (OR=1.43, CI=1.07, 1.90, p<0.05). This result 
seems counterintuitive, but running a regression without medical mistrust showed an 
insignificant result (OR=1.02, CI=0.78, 1.32, p=0.91), indicating co-linearity between medical 
mistrust and government mistrust. Both medical and government mistrust remained significant 
predictors after controlling for demographic characteristics (Table 12, Model 3).  
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Similar to Study 1, participants with a previous pregnancy (either their own or their 
partner’s, compared to those without a previous pregnancy) were less likely to choose DMD 
NBS (OR=0.71, CI=0.53, 0.95, p<0.05, Table 12, Model 3). Participants age 36 and older 
(compared to participants aged 21-35) and with a household income of $75,000 and over 
(compared to less than $35,000) were also less likely to choose DMD NBS (OR=0.60, CI=0.44, 
0.80, p<0.01; OR=0.60, CI=0.44, 0.82, p<0.01, respectively). As seen in Study 1 there was an 
effect of race. However, in Study 2 it was self-identifying as Asian that was a significant 
predictor: Asian participants (vs. white) were more likely to choose DMD NBS (OR=1.60, 




Table 12. Study 2 Test Characteristic and Demographic Predictors of Choosing DMD NBS 
 MODEL 1 (N=1,604) 
Baseline Regression 
MODEL 2 (N=1,539) 
+Attitudes 
MODEL 3 (N=1,378) 
+Demographics 






General Registry  
 
Reference 
0.94 (0.68, 1.31) 
0.72 (0.52, 0.99)* 
0.77 (0.56, 1.06) 
0.93 (0.67, 1.29) 
 
Reference 
0.95 (0.68, 1.33) 
0.71 (0.51, 0.99)* 
0.75 (0.54, 1.04) 
0.93 (0.67, 1.30) 
 
Reference 
0.97 (0.68, 1.40) 
0.69 (0.48, 0.99)* 
0.72 (0.50, 1.03) 
0.98 (0.68, 1.40) 
Altruism --- 1.04 (0.90, 1.21) 1.09 (0.93, 1.29) 
Need for Privacy --- 1.13 (1.00, 1.28) 1.14 (0.99, 1.31) 
Medical Mistrust --- 0.56 (0.46, 0.69)*** 0.54 (0.43, 0.67)*** 
Government Mistrust --- 1.43 (1.07, 1.90)* 1.43 (1.04, 1.95)* 
Age 
21 - 35 



















0.92 (0.56, 1.50) 
1.60 (1.03, 2.48)* 






























0.71 (0.53, 0.95)* 
Education Level 
College/Adv degree 
Some college/Tech  







1.08 (0.84, 1.39) 
0.89 (0.61, 1.30) 
Income 
<$35k 
$35k to <$75k 







0.79 (0.61, 1.03) 
0.60 (0.44, 0.82)** 
*p<0.05, **p<0.01, ***p<0.001 
 
Tables 13a-13d show the interactions of the moderating attitude variables and results 
release. The interaction model of altruism and results release presents significant findings 
showing how the effect of altruism was different for the different study groups (Table 13a). First, 
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there was a main effect of results release. When altruism was not a present characteristic, 
participants given DMD NBS with a private, biobank, DMD registry or general registry release 
were all less likely to choose DMD NBS than participants in the EHR results release group 
(private: OR=0.07, CI=0.01, 0.42, p<0.01; biobank: OR=0.09, CI=0.02, 0.47, p<0.01; DMD 
registry: OR=0.10, CI=0.02, 0.55, p<0.01; general registry: OR=0.16, CI=0.03, 0.94, p<0.05). 
Second, for only those participants in the EHR results release group, as their altruism scores 
increased they were less likely to choose DMD NBS (OR=0.67, CI=0.46, 0.99, p<0.05). And 
third, a robust interaction was found. There were changes to the main effect of altruism for each 
of the private, biobank, DMD registry, and general registry results release groups, with an 
increase in DMD NBS intent (private: OR=2.17, CI=1.30, 3.63, p<0.01; biobank: OR=1.88, 
CI=1.13, 3.14, p<0.05; DMD registry: OR=1.83, CI=1.10, 3.03, p<0.05; general registry: 
OR=1.69, CI=1.01, 2.84, p<0.05). So for participants in the EHR group, as altruism increased, 
intent decreased; for the other participants, as altruism scores increased there was an increase in 
DMD NBS intent. This was especially the case for those given privately-released DMD NBS. 
Similar to Table 12, need for privacy was not significant in the interaction model (Table 13b).  
Unpacking the main effect of medical mistrust shown in Table 12, the interaction model 
revealed that for those given DMD NBS with EHR results release, as medical mistrust increased 
participants were less likely to choose DMD NBS (OR=0.54, CI=0.35, 0.82, p<0.01; Table 13c). 
The interaction model of results release and government mistrust (Table 13d) presents an effect 
of the biobank results release group. When government mistrust was nonexistent, participants 
given a biobank results release were less likely to choose DMD NBS than those assigned to the 
EHR results release (OR=0.07, CI=0.01, 0.81, p<0.05). Age over 35, previous pregnancy, and 
income over $75,000 predicted being less likely to choose DMD NBS in all interactions.  
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Table 13b. Study 2 Predictors of Choosing DMD NBS, Interaction of Results Release and 
Need for Privacy (N=1,420)
a 









0.28 (0.02, 3.13) 
0.70 (0.07, 6.92) 
0.50 (0.04, 5.57) 
1.50 (0.12, 18.88) 
Need for Privacy 1.11 (1.02, 1.46) 
Interaction 
EHR x Privacy 
Private release x Privacy 
Biobank x Privacy 
DMD Registry x Privacy 
General Registry x Privacy 
 
Reference 
1.22 (0.82, 1.82) 
1.00 (0.69, 1.45) 
1.06 (0.72, 1.58) 
0.93 (0.62, 1.40) 
a
Controlled for demographics variables included in  
Table 12 Model 3.  
Significant control factors: Age 36+(p<0.01), African 
American race(p<0.05), previous pregnancy(p<0.05), 
household income $75k+ (p<0.01) 
*p<0.05 
 









0.07 (0.01, 0.42)** 
0.09 (0.02, 0.47)** 
0.10 (0.02, 0.55)** 
0.16 (0.03, 0.94)* 
Altruism 0.67 (0.46, 0.99)* 
Interaction 
EHR x Altruism 
Private release x Altruism 
Biobank x Altruism 
DMD Registry x Altruism 
General Registry xAltruism 
 
Reference 
2.17 (1.30, 3.63)** 
1.88 (1.13, 3.14)* 
1.83 (1.10, 3.03)* 
1.69 (1.01, 2.84)* 
a
Controlled for demographics variables included in  
Table 12 Model 3.  
Significant control factors: Age 36+(p<0.01), African 
American race(p<0.05), previous pregnancy(p<0.01), 




Table 13c. Study 2 Predictors of Choosing DMD NBS, Interaction of Results Release and 
Medical Mistrust (N=1,415)
a 









0.73 (0.13, 4.22) 
0.19 (0.03, 1.15) 
0.42 (0.07, 2.66) 
1.03 (0.15, 7.19) 
Medical Mistrust 0.54 (0.35, 0.82)** 
Interaction 
EHR x Mistrust 
Private release x Mistrust 
Biobank x Mistrust 
DMD Registry x Mistrust 
General Registry x Mistrust 
 
Reference 
1.11 (0.62, 1.98) 
1.56 (0.85, 2.86) 
1.21 (0.66, 2.24) 
1.00 (0.53, 1.88) 
a
Controlled for demographics variables included in  
Table 12 Model 3.  
Significant control factors: Age 36+(p<0.01), 




Table 13d. Study 2 Predictors of Choosing DMD NBS, Interaction of Results Release and 
Government Mistrust (N=1,409)
a 









0.84 (0.08, 8.82) 
0.07 (0.01, 0.81)* 
0.60 (0.05, 6.48) 
0.24 (0.02, 2.44) 
Government Mistrust 0.79 (0.43, 1.45) 
Interaction 
EHR x Mistrust 
Private release x Mistrust 
Biobank x Mistrust 
DMD Registry x Mistrust 
General Registry x Mistrust 
 
Reference 
1.05 (0.44, 2.50) 
2.28 (0.87, 5.54) 
1.08 (0.42, 2.60) 
1.64 (0.66, 3.87) 
a
Controlled for demographics variables included in  
Table 12 Model 3.  
Significant control factors: Age 36+(p<0.01), African 
American race(p<0.05), previous pregnancy(p<0.05), 





DMD NBS intent was also predicted by participants’ attitudes and subjective norms 
(Table 14). Similar to Study 1, there was an effect of attitudes about the importance of DMD 
NBS (Table 14, Model 1). Participants reporting higher importance of DMD NBS were 
considerably more likely to choose DMD NBS (OR=3.46, CI=2.86, 4.20, p<0.001), and 
participants reporting higher importance of seeing the DMD NBS results were more likely to 
choose DMD NBS (OR=1.59, CI=1.31, 1.92, p<0.001). These results held when considering 
participants’ attitudes about the impact of DMD NBS, which showed to be significant predictors 
as well (Table 14, Model 2).   
Participants reporting that the information from DMD NBS may help prepare for the 
future higher were more likely to choose DMD NBS (OR=1.81, CI=1.46, 2.24, p<0.001) and 
participants reporting worry about the DMD NBS results were less likely to choose DMD NBS 
(OR=0.84, CI=0.75, 0.95, p<0.01), consistent with Study 1 results. Additionally, participants 
reporting that the DMD NBS results may affect how they might treat their child were less likely 
to choose DMD NBS (OR=0.88, CI=0.79, 0.99, p<0.05).  
The influence of participants’ own subjective norms on DMD NBS intent was mixed 
(Table 14, Model 3). Participants reporting higher subjective norms around NBS in general had 
no difference in DMD NBS intent than those reporting lower subjective norms. However, 
participants reporting higher subjective norms around DMD NBS specifically were more likely 
to choose DMD NBS (OR=1.34, CI=1.16, 1.54, p<0.001).
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Table 14. Study 2 Attitude Predictors of Choosing DMD NBS
a
 









+ Attitudes about the 





+ Subjective norms 
 Mean (SD) OR (95% CI) OR (95% CI) OR (95% CI) 
Importance of DMD NBS 4.11 (1.00) 3.46 (2.86, 4.20)*** 3.12 (2.55, 3.81)*** 2.86 (2.32, 3.52)*** 
Importance of seeing the 
DMD NBS results 
4.45 (0.93) 1.59 (1.31, 1.92)*** 1.51 (1.24, 1.83)*** 1.53 (1.25, 1.86)*** 
Importance of sharing the 
DMD NBS results 
2.64 (1.30) 0.95 (0.84, 1.06) 0.97 (0.86, 1.09) 0.95 (0.85, 1.08) 
Worry about the DMD 
NBS results 
3.43 (1.19) --- 0.84 (0.75, 0.95)** 0.83 (0.74, 0.93)** 
The results may help 
prepare you for the future 
4.40 (0.76) --- 1.81 (1.46, 2.24)*** 1.63 (1.31, 2.03)*** 
The results may affect if 
you have more children 
3.17 (1.18) --- 0.91 (0.81, 1.02) 0.91 (0.80, 1.02) 
The results may affect how 
you might treat your child 
2.92 (1.33) --- 0.88 (0.79, 0.99)* 0.87 (0.78, 0.98)* 
The results may affect how 
others treat your child 
3.35 (1.12) --- 1.10 (0.96, 1.25) 1.10 (0.97, 1.26) 
Subjective norms around 
NBS in general 
5.51 (1.46) --- --- 0.97 (0.84, 1.11) 
Subjective norms around 
DMD NBS specifically 
5.40 (1.49) --- --- 1.34 (1.16, 1.54)*** 
a 
Models controlled for all factors in Table 12, Model 3.  
b 
Significant control factors: Medical mistrust (p<0.01), government mistrust (p<0.05), income 75K+ (p<0.01), 
previous pregnancy (p<0.05) 
c
 Significant control factors: Need for privacy (p<0.05), medical mistrust (p<0.05), income 75K+ (p<0.01), 
previous pregnancy (p<0.05) 
d 
Significant control factors: Need for privacy (p<0.05), medical mistrust (p<0.05), income 75K+ (p<0.01), 
previous pregnancy (p<0.05) 





The primary aim of Study 2 was to test the influences of the mode of results release on 
intended utilization of optional DMD NBS. Looking at the influence of the way in which the 
DMD NBS results would be released, participants in the biobank release group were less likely 
to choose DMD NBS than those in the EHR release group. However, there were no significant 
differences between the other modes of results release. These null findings could have occurred 
for two possible reasons: First, it is possible that the descriptions of the five modes (private 
release, EHR, biobank, DMD registry, and general registry) had too little variation in the 
characteristics that would either motivate or discourage utilization. Alternately, it is possible that 
people do care about mode of release but did not notice the variations across conditions because 
the study materials did not highlight them. I explore this explanation to some degree in Study 3. 
The interaction model of altruism and results release presents significant findings. 
Focusing on participants given the EHR results release, participants were less likely to choose 
DMD NBS as they reported increased altruism. The individual characteristic of altruism did not 
motivate DMD NBS intent for participants in the EHR release group, because that avenue of 
release had no societal implications. For the non-altruistic participants only, those in the private, 
biobank, DMD registry or general registry release groups were all less likely to choose DMD 
NBS than those in the EHR release group. Without the motivation of altruism participants did 
not choose DMD NBS when its results release would have larger societal contributions. The 
interaction effect confirmed these two main effects. Comparing all of the other results release 
groups, as participants’ were more altruistic they were more likely to choose DMD NBS. 
Overall, the findings related to altruism paint a picture about the appropriateness of tapping into 
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a participants’ such motives. Highly altruistic people are not guided by altruism to consent to a 
testing process if they know that they will not be giving a specific contribution by doing so.  
Additionally, the role of participants’ medical mistrust was significant; those reporting 
high medical mistrust were significantly less likely to choose DMD NBS than those reporting 
low mistrust. This result makes sense; participants who mistrust the institution involved in NBS 
would not want to engage in DMD NBS and previous research has shown trust in the medical 
community to be a central attitude to mothers making NBS decisions (Parsons et al., 2006). Such 
results should be taken into account when informing decision makers about NBS, or any medical 
procedure in general. The main effect for government mistrust was significant; participants 
reporting high government mistrust were significantly more likely to choose DMD NBS. 
Additional interaction analyses showed that when government mistrust was not an issue, 
participants in the biobank release group were still less likely to choose DMD NBS than those in 
the EHR release group. This result was unexpected; I hypothesized that it was government 
mistrust driving the reluctance to choose the DMD NBS with a biobank release. However, this 
counterintuitive finding might be explained by the measure’s colinearity with medical mistrust. 
There were no main or interaction effects for participants’ reported need for privacy.  
Increased likelihood of choosing DMD NBS was predicted by higher reported 
importance of DMD NBS in general and seeing the DMD NBS results. Importance of sharing the 
DMD NBS did not emerge as a significant predictor of DMD NBS intent. This finding may help 
explain why I did not see more robust results for the results release variable. Similar to Study 1 
participants reporting that the information from DMD NBS may help prepare for the future were 
more likely to choose DMD NBS, and participants reporting increased worry about the DMD 
NBS results were less likely to choose DMD NBS. A new attitude emerged in Study 2: 
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participants reporting that the DMD NBS results may affect how they might treat the child were 
less likely to choose DMD NBS. This finding is consistent with prior research that DMD NBS 
may lead to a disruption of the parent/newborn relationship (Bailey et al., 2009; Goddard & 
Cardinal, 2004). Although subjective norms around genetic testing in general did not predict 
DMD NBS intent, subjective norms around DMD NBS specifically did. Thus it is possible that 
in the context of optional testing, it is others’ opinions about the specific disease/test that matters.  
Similar to Study 1, having a previous pregnancy predicted lower likelihood of DMD NBS 
intent. Again I saw an effect of race, but it was self-identifying as Asian that predicted higher 
likelihood of DMD NBS intent. Participants with a high household income and participants over 
age 35 were less likely to choose DMD NBS than their counterparts, despite the general 
suggestion that pregnant women over 35 obtain increased genetic testing.  
Overall, these results tell a story of participants’ hesitancy to choose DMD NBS when the 
results would be released into a biobank, versus an electronic health record. Participants with low 
altruism or low government mistrust particularly followed this trend. For those assigned to an 
EHR release, high medical mistrust and high altruism predicted lower likelihood of choosing 
DMD NBS. Additionally, a set of significant attitude predictors emerged, consistent with Study 1 
and previous literature. Future DMD NBS pilot studies might address medical mistrust as a 
personal characteristic that biases decision making, and align decision makers’ altruistic goals 
with their ideal mode of results release. Although Study 2 did find robust results with the 
moderating variables, only two study groups were significantly different. These two groups stood 
at the far ends of a spectrum: EHR release represented testing with a truly individual goal, and 
biobank release represented testing with a larger goal to benefit research. These two distinctions 






The results from Study 2 showed an effect of only 1 type of results release, a biobank 
release compared to an electronic health records release. After looking at these results I noted 
that the groups from Study 2 were nuanced with too little variation in release characteristics 
between them, especially considering the 2 registry groups. Therefore I developed a third study 
to look at the theoretical extremes of results release to explore the greatest variation possible, 
focusing on the driving purpose behind each release type instead of each possible deviation.  
Study 3 examined two possible influences on DMD NBS decision making. First, I 
examined how the purpose for which the DMD NBS results are released may influence the initial 
decision to utilize DMD NBS. I did not emphasize the specific way that DMD NBS results are 
released, but instead the overall purpose of the testing that guided the release. Second, I 
investigated the perceived vulnerability of the child to receive a positive DMD NBS test result, 
varying from no history to non-genetic health problems at birth.  
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Figure 4. Study 3 Conceptual Model 
 
 
The conceptual model for Study 3 (Figure 4, above) describes hypothesized influences on 
the intent to utilize DMD NBS. The model is drawn from the model in Study 2; there are two 
main action steps in the DMD NBS process: 1. utilizing the NBS; 2. releasing the NBS results. 
However in Study 3 I focused on the overall purpose of DMD NBS and hypothesized that it 
influences DMD NBS intention (H1), as opposed to the specific avenues of release. The test 
purpose is an important construct; previous research has shown that parents requesting 
information look for information about the nature and purpose of NBS and not the technical 
details (Campbell & Ross 2004). Just as in Study2, I hypothesized that this relationship would be 
moderated by a person’ attitudes towards the following: altruism, need for privacy, medical 
mistrust, and government mistrust (H1a).  
I hypothesized that participants who read a scenario in which their child was vulnerable 
to DMD (i.e. had a DMD family history) would be more likely to choose DMD NBS than those 
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with a no history scenario (H2). This effect of perceived vulnerability would also be seen in the 
other conditions; I hypothesized that there would be a difference in DMD NBS intent between 
the no history condition and the epilepsy history and premature birth conditions. This construct 
perceived vulnerability would also interact with test purpose (H1b). Similar to both Study 1 and 
2, I hypothesized that attitudes towards DMD NBS would predict DMD NBS intent (H3). In 
addition to predictors of DMD NBS intent, Study 3 addressed influences on attitudes towards 
DMD NBS. I assessed the association between attitudes and the two study factors, test purpose 
(H4) and perceived vulnerability (H5).  
Study Aims and Hypotheses 
Primary Aim: To examine the influences on intended utilization of DMD NBS.  
H1: Participants presented with DMD NBS for research purposes will report lower DMD NBS 
intention, compared to participants presented with DMD NBS for personal purposes 
a) This relationship is moderated by attitudes towards altruism, need for privacy, 
medical mistrust, and mistrust in government, such that the hypothesized relationship 
will be mitigated for those with high altruism and attenuated for those with high need 
for privacy, high medical mistrust, and high government mistrust. 
b) This relationship is moderated by participants’ perceived vulnerability as manipulated 
in the scenario 
H2: Participants presented with a high vulnerability scenario will report higher DMD NBS 
intention, compared to participants presented with no DMD NBS history 




Secondary Aim: To examine the influences of the experimental factors on attitudes about 
optional DMD NBS 
H4: Participants presented with DMD NBS for personal purposes will report more positive 
attitudes about DMD NBS, compared to participants presented with DMD NBS for research 
purposes  
H5: Participants with more relevant perceived vulnerability will report more positive attitudes 
about DMD NBS  
Study Design  
Study 3 had a 4x2 between-subjects experimental design: perceived vulnerability (no 
family history of DMD, family history of DMD, family history of another neurological disease, 
premature birth) x test purpose (personal, research). Participants were randomly assigned to one 
of the eight experimental groups: 
  Perceived Vulnerability 








Test Personal  1 2 3 4 
Purpose Research 5 6 7 8 
 
Perceived vulnerability describes how vulnerable the decision makers think the child is 
for DMD. Participants were randomized to one of the four groups that varied by the level of 
perceived vulnerability, based on a manipulation of the study scenario: for the no family history 
group, the scenario described a situation in which no family history of DMD was specified or 
implicated. The family history of DMD group was just that: the scenario specified that there was 
a family history of DMD and the doctor wanted to have a further conversation about this history. 
The participant had already read about DMD so he/she knew that DMD has a genetic 
component. Participants assigned to the family history of another neurological disease group 
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read a scenario in which the doctor wanted to have a conversation about a family history of 
Epilepsy, which was described as a neurological disorder that causes seizures. The purpose of 
this group was to test whether participants associated the vulnerability of one disorder that 
affects the brain with the vulnerability of another disorder that affects the brain, despite the 
massive differences between the two in etiology and health outcomes. The final group read a 
scenario in which the child was born prematurely and required medical attention at birth, and 
would require continual medical attention in the future. The purpose of this group was to test 
whether participant associated a child’s overall medical vulnerability with the vulnerability of a 
specific disorder with a genetic component. 
The test purpose described the overall purpose of the DMD NBS that guided what would 
happen to the information from the DMD NBS results. Participants were randomly assigned to 
one of two groups based on the study design and the study materials: personal; and research. 
Participants in the personal purpose group read about DMD NBS done for their family benefit 
only. For this group, the results would not released to anyone not associated with the family for 
larger societal goals; in this way the group was theoretically similar to the Study 2 private and 
EHR release groups. Participants in the research group read about DMD NBS with the societal 
aims of improving future treatment and testing options for DMD. The results would be viewable 
not only to the family, but also to unrelated others in order to reach this goal. This group took a 
broader, more theoretical approach to the Study 2 biobank, DMD registry, and general registry 







Summary of Methodology 
 The methodology for Study 3 was identical to that of Study 2. Briefly, participants above 
the age of 21, living in the United States and able to complete a web-based survey were paid 
$0.75 to complete an MTurk-administered Internet study. To begin each study, participants read 
a vignette that outlined a hypothetical situation in which they have a newborn son and then a 
brochure that provided a detailed description of DMD, DMD NBS, and DMD NBS results (See 
Appendix H for Study 3 vignettes and Appendix I for Study 3 brochures). The vignettes differed 
by how the vulnerability of child to DMD was presented in the scenario, following the study 
design. The study brochures differed by their description of the DMD NBS. Half presented the 
overall purpose of DMD NBS as a personal one, and half presented the purpose as a larger 
societal one to advance research. Then participants completed survey items that measured DMD 
NBS intention, attitudes and beliefs, subjective norms, attitudes towards altruism, need for 
privacy, medical mistrust, government mistrust, and demographics (described in Study 1 and 
Study 2 chapters; see Appendix E for full items). Sample size calculations were identical as for 
Study 2; a sample size of N=310 per cell, or N=2,480 total was needed for Study 3.   
Data Analyses 
To test the main effects of perceived vulnerability and test purpose, I used ANOVA to 
compare the mean across the experimental groups of intended DMD NBS utilization scores and 
bonferroni post-hoc pairwise comparisons to see which means were different from each other. 
Then I used ordered logistic regressions to test whether perceived vulnerability, test purpose, and 
the interaction of the two predicted DMD NBS choice. I used logistic regressions to test for main 
effects of altruism, need for privacy, medical mistrust, and government mistrust on DMD NBS 
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choice, as well as interactions with test purpose. To test whether attitudes towards DMD NBS 
predicted DMD NBS choice I created two logistic regression models: the first included attitudes 
about the importance of DMD NBS; the second added attitudes about the impact of DMD NBS. 
All regressions controlled for age, race, gender, marital/partnered status, previous pregnancy, 
level of education, and household income. 
Results 
A total of 3,090 surveys were completed. Participants were predominately white (80.9%), 
female (52.0%), unmarried/unpartnered (53.7%), and had no children (65.2%). The average age 
was 31.6 (range 21-82). Participants mostly had a college degree (42.4%) and had a household 




Table 15. Study 3 Participant Characteristics (N=3,090)
a
 
 % (N) 
Age (range, mean) 
21-35 








































$14.5 to <$35k 
$35k to <$50k 
$50k to <$75k 
$75k - <$100k 


















Number of Children 
0 
1 






N varies due missing data. Percentage of 
missing data < 0.50% for all variables 
except for age (7.6% missing) 
b





The primary aim was to test the influences on intended optional DMD NBS. I studied the 
effect of the overall test purpose. There was a significant difference between the personal test 
purpose group and the research test purpose group’s mean scores for likelihood of choosing 
DMD NBS (t=3.40, p<0.001, see Table 16). The baseline regression model showed no main 
effect of test purpose on DMD NBS choice, indicating an interaction effect (Table 17). Looking 
at varying degrees of child’s health that would drive perceived vulnerability, there was a 
significant difference between the mean scores for likelihood of choosing DMD NBS across the 
four groups (F=18.58, p<0.001, see Table 16). Post-hoc analyses revealed participants’ DMD 
NBS intent in the highest perceived vulnerability group (DMD history) was significantly higher 
than that of participants in all 4 other groups. Additional group differences included the no 
history group and the premature birth group; participants whose hypothetical newborns were 
born prematurely had higher DMD NBS intent. There was no group difference in DMD NBS 
intent between the premature birth group and the neurological history (epilepsy history) group. 
Using the no disease history as the reference category, there was a main effect of perceived 
vulnerability (Table 17, Model 1). Participants whose hypothetical child had a family history of 
DMD were much more likely to choose DMD NBS than participants whose child had no family 
history (OR=3.07, CI=2.21, 4.26, p<0.001). Additionally, compared to participants in the no 
history scenario, participants whose hypothetical child had either a family history of epilepsy or 
were born prematurely were more likely to choose DMD NBS (OR=1.43, CI=1.08, 1.90, p<0.05; 
OR=1.57, CI=1.18, 2.08, p<0.01, respectively).  
An interaction was found between test purpose and perceived vulnerability; there was a 
change to the main effect of test purpose when participants’ scenario included either a history of 
DMD or a history of epilepsy. Participants in these groups were less likely to choose DMD NBS 
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when the test was for a research purpose compared to a personal purpose (OR=0.60, CI=0.39, 
0.92, p<0.05; OR=0.66, CI=0.45, 0.97, p<0.05, respectively). These results were still significant 
after including demographic characteristics and attitude factors (Table 17, Models 2 and 3). 





















3.29 (0.94) 3.68 (0.73) 3.43 (0.90) 3.49 (0.83) 3.47 (0.87) 
Research 3.28 (0.98) 3.55 (0.80) 3.28 (0.94) 3.36 (0.92) 3.36 (0.92) 
Total Mean (SD)
c 
3.29 (0.96) 3.61 (0.77) 3.35 (0.92) 3.43 (0.88)  
a
Mean (SD); 1=very unlikely, 4=very likely 
b
Difference between means across test purpose groups t=3.40, p<0.001 
c
Difference between means across perceived vulnerability groups F=18.58, p<0.001 
 
In addition to the manipulated condition, race predicted the likelihood of choosing DMD 
NBS (Table 17, Model 2). African American participants (compared to white participants) were 
less likely to choose DMD NBS (OR=0.54, CI=0.41, 0.73, p<0.001). Adding demographic 




Table 17. Study 3 Test Characteristic and Demographic Predictors of Choosing DMD NBS 
 MODEL 1 (N=3,090) 
Baseline Regression 
MODEL 2 (N=2,812) 
+Demographics 










1.01 (0.77, 1.32) 
 
Reference 
1.02 (0.77, 1.35) 
 
Reference 










3.07 (2.21, 4.26)*** 
1.43 (1.08, 1.90)* 




3.04 (2.16, 4.30)*** 
1.44 (1.06, 1.94)* 




3.02 (2.12, 4.31)*** 
1.47 (1.08, 2.00)* 
1.65 (1.22, 2.25)** 
Interaction 
No History x 
Research 
DMD History x  
Research 
Epilepsy History x  
Research 





0.60 (0.39, 0.92)* 
 
0.66 (0.45, 0.97)* 
 




0.62 (0.39, 0.99)* 
 
0.65 (0.43, 0.98)* 
 




0.62 (0.39, 0.99)* 
 
0.63 (0.41, 0.96)* 
 
0.70 (0.46, 1.07) 
Age 
21-35 





0.91 (0.76, 1.10) 
 
Reference 










0.54 (0.41, 0.73)*** 
0.77 (0.58, 1.03) 
0.88 (0.62, 1.24) 
 
Reference 
0.58 (0.43, 0.78)*** 
0.80 (0.59, 1.07) 








1.10 (0.94, 1.28) 
 
Reference 








0.93 (0.78, 1.11) 
 
Reference 








0.89 (0.74, 1.07) 
 
Reference 









0.88 (0.74, 1.04) 
0.88 (0.68, 1.14) 
 
Reference 
0.90 (0.76, 1.07) 











$35k to <$75k 
$75k and over 
0.93 (0.78, 1.11) 
0.90 (0.72, 1.12) 
0.95 (0.80, 1.15) 
0.93 (0.74, 1.16) 
Altruism --- --- 1.09 (0.97-1.22) 
Need for Privacy --- --- 1.13 (1.04-1.23)** 
Medical Mistrust --- --- 0.61 (0.50-0.74)*** 
Government Mistrust --- --- 1.10 (0.97-1.24) 
*p<0.05, **p<0.01, ***p<0.001 
 
Neither altruism nor government mistrust were significant main predictors of DMD NBS 
choice (see Table 17, Model 3). However there was a main effect of need for privacy and 
medical mistrust. Participants with a higher need for privacy were more likely to choose DMD 
NBS, somewhat counterintuitively (OR=1.13, CI=1.04, 1.23, p<0.01). A main effect of medical 
mistrust showed that participants with higher medical mistrust were less likely to choose DMD 
NBS (OR=0.61, CI=0.50, 0.74, p<0.001).  
 I also assessed the interactions of the moderating attitude variables and DMD NBS 
choice, controlling for the main and interaction effects as well as demographic characteristics in 
Table 17 Model 3. Similar to Table 17 Model 3, neither altruism nor government mistrust 
showed interaction effects (see Tables 18a and 18d). No interaction effects were found for either 
need for privacy (Table 18b) or medical mistrust (Table 18c). For all of the moderating analyses 
African American race remained a significant control factor of being less likely to choose DMD 










Table 18b. Study 3 Predictors of Choosing DMD NBS, Interaction of Test Purpose and 
Need for Privacy (N=2,794)
a 






1.19 (0.44, 3.23) 
Need for Privacy 1.15 (1.02, 1.30)* 
Interaction 
Privacy x Purpose 
 
1.07 (0.91, 1.26) 
a
Model controlled for all factors in Table 17, Model 2. 
Significant control factors: DMD history(p<0.001), epilepsy 
history (p<0.05), premature birth (p<0.01), DMD history/ 
research interaction (p<0.05), epilepsy history/ research 
interaction (p<0.05), African American race (p<0.001) 
*p<0.05 
 
Table 18c. Study 3 Predictors of Choosing DMD NBS, Interaction of Test Purpose and 
Medical Mistrust (N=2,776)
a 






0.39 (0.12, 1.25) 
Medical Mistrust 0.58 (0.44, 0.76)*** 
Interaction 
Medical Mistrust x Purpose 
 
0.81 (0.56, 1.16) 
a
Model controlled for all factors in Table 17, Model 2. 
Significant control factors: DMD history(p<0.001), epilepsy 
history (p<0.05), premature birth (p<0.01), DMD history/ 
research interaction (p<0.05), epilepsy history/research 
interaction (p<0.05), African American race (p<0.001) 
***p<0.001  






0.76 (0.37, 1.57) 
Altruism 1.07 (0.91, 1.25) 
Interaction 
Altruism x  Purpose 
 
1.00 (0.81, 1.24) 
a
Controlled for all factors in Table 17, Model 2.  
Significant control factors: DMD history(p<0.001), epilepsy 
history (p<0.05), premature birth (p<0.01), DMD history/ 
research interaction (p<0.05), epilepsy history/research 
interaction (p<0.05), African American race (p<0.001) 
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 Table 18d. Study 3 Predictors of Choosing DMD NBS, Interaction of Test Purpose and 
Government Mistrust (N=2,783)
a 






0.63 (0.36, 1.10) 
Government Mistrust 1.03 (0.87, 1.23) 
Interaction 
Government Mistrust x 
Purpose 
 
0.92 (0.73, 1.16) 
a
Model controlled for all factors in Table 17, Model 2. 
Significant control factors: DMD history(p<0.001), epilepsy 
history (p<0.05), premature birth (p<0.01), epilepsy history/ 
research interaction (p<0.05), African American race 
(p<0.001) 
 
DMD NBS intent was also predicted by participants’ attitudes and subjective norms 
(Table 19). A baseline regression model explored attitudes about DMD NBS importance. Similar 
to the previous studies, I found an effect of attitudes about the importance of DMD NBS (Table 
19, Model 1). Participants reporting higher importance of DMD NBS were more likely to choose 
DMD NBS (OR=2.67, CI=2.35, 3.03, p<0.001), and participants reporting higher importance of 
seeing the DMD NBS results were more likely to choose DMD NBS (OR=1.89, CI=1.67, 2.13, 
p<0.001).  
The likelihood of choosing DMD NBS was also predicted by two attitudes about the 
impact of DMD NBS (Table 19, Model 2). Participants who reported that the information from 
DMD NBS may help prepare for the future were more likely to choose DMD NBS (OR=1.80, 
CI=1.57, 2.06, p<0.001), and participants reporting worry about the DMD NBS results were less 
likely to choose DMD NBS (OR=0.70, CI=0.64, 0.75, p<0.001). These results are consistent 
with previous findings. The impact of DMD NBS results on reproductive planning, how you 
might treat your child, and how others might treat your child were not significant predictors in 
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this model. Adding these additional attitude measures did not change the significance of reported 
importance of DMD NBS.  
Participants did not put equal weight on subjective norms around NBS in general and 
around DMD NBS specifically (Table 19, Model 3). Subjective norms around NBS in general 
did not predict DMD NBS intent, but participants reporting higher subjective norms around 
DMD NBS specifically were more likely to choose DMD NBS (OR=1.18, CI=1.07, 1.30, 
p<0.01). All regression models in Table 19 controlled for test purpose, perceived vulnerability, 
attitude measures and demographic characteristics included in Model 3 of Table 17. 
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Table 19. Study 3 Attitude Predictors of Choosing DMD NBS
a
 









+ Attitudes about the 





+ Subjective norms 
 Mean (SD) OR (95% CI) OR (95% CI) OR (95% CI) 
Importance of DMD NBS 4.11 (1.00) 2.67 (2.35, 3.03)*** 2.64 (2.31, 3.01)*** 2.36 (2.06, 2.71)*** 
Importance of seeing the 
DMD NBS results 
4.45 (0.93) 1.89 (1.67, 2.13)*** 1.64 (1.45, 1.86)*** 1.58 (1.40, 1.80)*** 
Importance of sharing the 
DMD NBS results 
2.64 (1.30) 1.01 (0.94, 1.09) 1.02 (0.95, 1.11) 1.01 (0.93, 1.09) 
Worry about the DMD 
NBS results 
3.43 (1.19) --- 0.70 (0.64, 0.75)*** 0.69 (0.63, 0.74)*** 
The results may help 
prepare you for the future 
4.40 (0.76) --- 1.80 (1.57, 2.06)*** 1.72 (1.50, 1.97)*** 
The results may affect if 
you have more children 
3.17 (1.18) --- 1.05 (0.97, 1.14) 1.04 (0.95, 1.13) 
The results may affect how 
you might treat your child 
2.92 (1.33) --- 0.95 (0.88, 1.03) 0.94 (0.87, 1.02) 
The results may affect how 
others treat your child 
3.35 (1.12) --- 1.01 (0.93, 1.11) 1.02 (0.93, 1.11) 
Subjective norms around 
NBS in general 
5.51 (1.46) --- --- 1.06 (0.96, 1.16) 
Subjective norms around 
DMD NBS specifically 
5.40 (1.49) --- --- 1.18 (1.07, 1.30)** 
a
Models controlled for all factors in Table 17, Model 3 
b 
Significant control factors: DMD history (p<0.05), altruism (p<0.05), medical mistrust (p<0.001), African 
American race (p<0.001), other race (p<0.05), high school education or less (p<0.01), some college (p<0.01) 
c
 Significant control factors: DMD history (p<0.01), premature birth (p<0.05), altruism (p<0.05), privacy (p<0.05), 
medical mistrust (p<0.01), African American race (p<0.05), HS education or less (p<0.01), some college (p<0.01) 
d
 Significant control factors: DMD history (p<0.01), premature birth (p<0.05), altruism (p<0.05), privacy (p<0.05), 
medical mistrust (p<0.01), African American race (p<0.05), HS education or less (p<0.01), some college (p<0.01) 
*p<0.05, **p<0.01, ***p<0.001 
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The secondary aim was to look at the effect of the manipulated study conditions on DMD 
NBS attitudes. There were robust results when comparing perceived vulnerability groups (Table 
20). Participants in the different study groups significantly differed in their report of the 
importance of DMD NBS. Participants with the highest vulnerability group (the DMD history 
scenario) reported DMD NBS, seeing the DMD NBS results, and sharing the DMD NBS results 
most important (F=55.37 p<0.001, F=16.48 p<0.001, F=4.96, p<0.001, respectively). For each 
of these three importance measures, the order of most to least important went: DMD history, 
epilepsy history, premature birth, and no history. Participants with the DMD history scenario 
also reported greatest worry about the DMD NBS results (F=59.39, p<0.001), how much the 
results would prepare them for the future (F=20.01, p<0.001), whether the results would affect 
whether they had more children (F=17.98, p<0.001). Interestingly, when asked about whether 
the results would affect how they might treat the child, DMD history did not come into play; 
participants in the epilepsy history scenario were significantly higher than the lowest score, 
premature birth (F=2.85, p<0.05). There was no significant difference between groups in 
whether the results would affect how others might treat the child.  
Participants’ own subjective norms (i.e. reporting how they think what most other people 
believe) were associated with perceived vulnerability; those in the highest vulnerability scenario 
reported higher norms around the endorsement of both NBS in general and DMD NBS 




Table 20. Attitudes about DMD NBS, by Perceived Vulnerability 
















Importance of DMD 
NBS  
3.74 (1.14) 4.42 (0.87) 3.97 (1.05) 3.95 (1.10) F=55.37*** 
Importance of seeing 
the DMD NBS results 
4.21 (1.14) 4.57 (0.84) 4.36 (1.02) 4.31 (1.04) 
 
F=16.48*** 
Importance of sharing 
the DMD NBS results 
2.87 (1.33) 3.13 (1.35) 2.98 (1.36) 2.94 (1.37) F=4.96*** 
Worry about the DMD 
NBS results 
3.14 (1.33) 3.95 (1.12) 3.30 (1.26) 
 
3.52 (1.26) F=59.39*** 
The results may help 
prepare you for the 
future 
4.22 (0.88) 4.53 (0.71) 4.36 (0.76) 4.36 (0.80) F=20.02*** 
The results may affect 
if you have more 
children 
3.14 (1.18) 3.56 (1.11) 3.30 (1.16) 3.25 (1.20) 
 
F=17.98*** 
The results may affect 
how you might treat 
your child 
2.83 (1.34) 2.87 (1.38) 2.96 (1.33) 
 
2.77 (1.38) F=2.85* 
The results may affect 
how others treat your 
child 
3.26 (1.16) 3.29 (1.21) 3.23 (1.21) 3.24 (1.14) F=0.40 
Subjective norms 
around NBS in general 
5.35 (1.56) 5.69 (1.51) 
 
5.53 (1.51) 5.45 (1.59) F=6.47*** 
Subjective norms 
around DMD NBS 
5.19 (1.65) 5.91 (1.33) 5.43 (1.55) 5.45 (1.55) F=28.12*** 
*p<0.05, **p<0.01, ***p<0.001 
 
There was a group difference in multiple attitude measures between the test purpose 
groups (Table 21). Participants presented with DMD NBS for personal purposes found DMD 
NBS to be more important (t=4.53, p<0.001) and reported higher subjective norms around NBS 
in general and DMD NBS specifically (t=3.10, p<0.001; t=3.82, p<0.001, respectively). 
However, participants presented with DMD NBS for research purposes reported that sharing 




Table 21. Attitudes about DMD NBS, by Test Purpose 







Importance of DMD 
NBS 
4.10 (1.05) 3.92 (1.10) t= 4.53*** 
Importance of seeing 
the DMD NBS results 
4.38 (1.01) 4.33 (1.04) t= 1.37 
Importance of sharing 
the DMD NBS results 
2.91 (1.36) 3.04 (1.34) t= -2.60* 
Worry about the DMD 
NBS results 
3.49 (1.27) 3.44 (1.30) t=1.00 
The results may help 
prepare you for the 
future 
4.39 (0.79) 4.34 (0.81) t=1.88 
The results may affect 
if you have more 
children 
3.29 (1.17) 3.32 (1.17) t=-0.54 
The results may affect 
how you might treat 
your child 
2.85 (1.36) 2.87 (1.36) t=-0.28 
The results may affect 
how others treat your 
child 
3.26 (1.15) 3.26 (1.17) t=0.01 
Subjective norms 
around NBS in general 
5.59 (1.51) 5.42 (1.58) t= 3.10*** 
Subjective norms 
around DMD NBS 
5.59 (1.49) 5.38 (1.59) t= 3.82*** 
*p<0.05, **p<0.01, ***p<0.001 
 
Discussion 
The primary aim of Study 3 was to test the influences on intended utilization of optional 
DMD NBS, addressing the Study 2 results by considering the overall DMD NBS purpose as 
opposed to the nuanced modes of results release. A main effect of perceived vulnerability 
showed that participants whose hypothetical child had a family history of DMD were much more 
likely to choose DMD NBS than participants whose child had no DMD family history. However 
other unrelated family histories and health statuses also influenced uptake of DMD NBS; 
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participants whose hypothetical newborn had either a family history of epilepsy or a premature 
birth were more likely to choose DMD NBS than participants whose child had no DMD family 
history. Logically, these two conditions should not differ in DMD NBS intent from the no family 
history group. This result speaks to an overall sense of vulnerability; participants have a gist 
reaction to a genetic vulnerability involving a similar part of the body (epilepsy history) or basic 
health vulnerability (premature birth) and transfer it to vulnerability for other diseases (e.g. 
DMD).  
The purpose of DMD NBS (research vs. personal) did not predict DMD NBS as a main 
effect. Although this null finding is consistent with the null finding of Study 2, it does not tell the 
whole story of the role of test purpose. The Study 3 data show important interactions of test 
purpose with the perceived vulnerability to DMD when participants’ scenario included a history 
of DMD. Participants whose hypothetical newborn had a history of DMD or a history of epilepsy 
were less likely to choose DMD NBS when it had a research (vs. personal) purpose. This finding 
indicates that perceived vulnerability to the disease heightens the perceived value of DMD NBS 
when the screening focuses on personal (vs. research) benefits. This has implications for both the 
presentation of screening: emphasizing the personal stakes of research, and how it may help 
participants individually, appears likely to increase consent among those with a personal history 
of the disease. The results also showed that participants given a family history of epilepsy 
responded similarly to those with a history of DMD; this may indicate that people see their child 
with a gist vulnerability when reacting to the personal stakes of research. A similar, albeit non-




Neither altruism nor government mistrust provided significant main/interaction effects, 
the former being inconsistent with previous findings. Tabor et al. (2011) found that one of the 
five main influences of parents’ decisions to participate in NBS research is level of altruism. 
However participants reporting high medical mistrust were less likely to choose DMD NBS, 
consistent with previous findings (Parsons et al., 2006). Additionally, participants reporting a 
high need for privacy were more likely to choose DMD NBS. The lack of interaction effects 
makes this result difficult to interpret.  
Study 3 confirmed the trend seen in Studies 1 and 2 of DMD NBS intent predicted by 
attitudes about DMD NBS. Participants reporting higher importance of DMD NBS in general 
and seeing the DMD NBS results were more likely to choose DMD NBS. Congruent with 
previous work, participants reporting that the information from DMD NBS may help prepare for 
the future were more likely to choose DMD NBS (Parsons et al., 2006; Pelias, 2006), and 
participants reporting increased worry about the DMD NBS results were less likely to choose 
DMD NBS (DeLuca et al., 2011; Waisbren et al., 2003). Similar to Study 2, subjective norms 
around NBS in general did not predict DMD NBS intent, but participants reporting higher 
subjective norms around DMD NBS specifically were more likely to choose DMD NBS, 
indicating that specificity of subjective norms is important.  
The secondary aim was to look at the influences on DMD NBS attitudes. Participants 
given the DMD history scenario had the strongest attitudes about DMD NBS; they reported the 
highest importance of DMD NBS, seeing the DMD NBS results, and sharing the DMD NBS 
results. This is a logical finding; with the personal connection to the disease participants would 
favor NBS. Although participants presented with DMD NBS for personal purposes also found 
DMD NBS to be more important, participants presented with DMD NBS for research purposes 
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reported that sharing DMD NBS results to be more important. Participants given the DMD 
history scenario reported the greatest worry about the DMD NBS results, and the most that the 
results would prepare them for the future and affect whether they had more children. However a 
history of DMD was not a significant factor regarding whether the DMD NBS results would 
affect how participants might treat their hypothetical child; instead, participants given a scenario 
with a history of epilepsy were more likely to answer affirmatively. Participants’ own subjective 
norms (i.e. reporting how they think what most other people believe) were associated with both 
study factors; those in the highest vulnerability scenario and participants presented with DMD 
NBS for personal purposes reported higher norms around the endorsement of both NBS in 
general and DMD NBS specifically. 
Participants who were African American (vs. white) were less likely to choose DMD 
NBS, echoing findings in the previous dissertation studies and by others (Corbie-Smith et al., 
2002; Corbie-Smith et al., 1999; Furr, 2022).  
Overall, these results communicate that perceived vulnerability to a disorder should not 
be overlooked. Not only does vulnerability to the relevant disease (e.g. a history of DMD) 
influence testing decisions, it also influences attitudes towards the test and can change the way 
people feel about testing for research vs. personal purposes. Interestingly, it appears that 
vulnerability can be perceived when there is no history of the relevant disease, but instead other 
health risks. People may process a vulnerability gist concept, instead of focusing on one etiology 
versus another, and their interest in DMD NBS appears more driven by that gist perception of the 
child as vulnerable to disease. In addition, Study 3 showed the value of considering test purpose 
as the overarching, driving force behind the release of results rather than in terms of the 
narrower, functional definitions used in Study 2. There was an effect of test purpose, in that 
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perceived vulnerability heightened participants’ perceived value of DMD NBS when primed to 
consider it for a personal purpose. However when the presentation of DMD NBS focused on a 








The focus of this dissertation is whether variation in presentation and characteristics of a 
medical test influences utilization. To address this larger question I looked specifically at 
optional newborn screening (NBS), a choice that parents can face in addition to mandatory NBS. 
This is an issue worth studying because, while parents are not in a decision-making role 
regarding mandatory NBS panels, with the continued expansion of NBS parents may be 
increasingly faced with the decision to utilize additional optional NBS. However there is no 
consistent policy regarding optional NBS communication, in terms of the information included 
and the way in which this information is presented (Hargreaves et al., 2005; Loeben et al., 1998). 
These questions will become more and more important because NBS programs are likely to 
continue expanding, increasingly including diseases for which limited information about 
treatment efficacy is available at minimal incremental cost (Carroll & Downs, 2006; Insinga et 
al., 2002; Schoen et al., 2002).  
Findings 
In three separate randomized experimental studies I examined possible influences on 
optional NBS using Duchenne muscular dystrophy (DMD) as an exemplar. DMD provided an 
ideal paradigm; despite the development of DMD NBS, no treatment is widely used that can alter 
the disease course of DMD. Therefore learning one’s DMD status does not improve clinical 
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outcomes. Previous pilot programs have offered DMD NBS as an optional NBS but no states 
have thus far included it their mandatory NBS panels. 
Study 1   
Study 1 explored the test presentation characteristic of bundling mandatory NBS panels 
with which optional NBS is presented. DMD NBS is presented in the context of mandatory NBS 
panels; although it is known that unbundling NBS invitations decreases utilization, as opposed to 
bundling the optional NBS test offer and the mandatory NBS tests (Moody & Choudhry, 2011), 
this finding did not extend to mandatory NBS panels. Instead, the Study 1 findings showed that it 
is whether the context of mandatory NBS is discussed in any way (bundled or unbundled) that 
influences DMD NBS intent. This finding indicates that when participants were not given the 
context of broader mandatory NBS in which to place a specific optional NBS, they were more 
hesitant to choose testing. The results suggest that viewing DMD NBS information without the 
larger perspective of mandatory NBS tempers DMD NBS intent and attitudes about DMD NBS. 
Future optional NBS programs should be careful to sufficiently present the testing information in 
a way that provides decision makers with a context in which to understand how that single NBS 
test fits into NBS overall.  
Study 2 
Study 2 focused on a post-test influence on test decision making that can vary from test to 
test: the specific test feature of how the NBS results are released. The study addressed whether 
advance knowledge about NBS results release and related attitudes affects DMD NBS. Although 
there was no main effect of the modes of results release (private, electronic health record, 
biobank for future research, DMD registry, and general registry) on DMD NBS intent, two 
groups differed: participants given a biobank results release were less likely to choose DMD 
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NBS than those given an EHR release. However, the relatively small effect sizes observed may 
be attributed to the degree to which I implemented the experimental condition; I used nuanced 
group divisions (e.g. DMD registry vs. regular registry) and the participants may not have picked 
up on the subtle differences between the modes of results release. Therefore I re-examined the 
overarching concept of test purpose that drives results release in a third study.  
However, Study 2 did find that increased medical mistrust was as a significant predictor 
of low DMD NBS intent. This finding is consistent with previous work showing trust in the 
medical community was central to the attitudes of the mothers considering NBS (Parsons et al., 
2006). It also has implications for future NBS program recruitment, signaling that gaining trust, 
or at least addressing possible existing mistrust, is an important step that might remove testing 
barriers. The unexpected finding that increased government mistrust predicted DMD NBS intent, 
may be explained by the measure’s colinearity with medical mistrust.  
In addition, Study 2 found a significant interaction of results release and altruism. For the 
non-altruistic participants, those not in the EHR release group were less likely to choose DMD 
NBS compared to those in the EHR release group, and participants in the EHR results release 
were less likely to choose DMD NBS as they reported increased altruism. These participants’ 
altruistic motives had no outlet the EHR condition; there are no philanthropic implications of 
EHR results release. The interaction showed that comparing all of the other results release 
groups to EHR, as the more altruistic participants were, the more they were likely to choose 
DMD NBS. These robust findings have implications for future recruitment in NBS programs. 
Appealing to possible participants’ sense of altruism may only be successful if they know their 





Study 3 re-examined the results release construct from Study 2, looking at the theoretical 
extremes to focus on the overarching purpose of the test that drives the mode of results release. 
The main purpose of DMD NBS (research vs. personal) did not have an effect on DMD NBS 
intention in the absence of perceived vulnerability sources (e.g. family history), even though the 
manipulation was more robust than in Study 2. However, interactions with the perceived 
vulnerability to DMD showed that participants whose hypothetical newborn had a history of 
DMD or a history of epilepsy were less likely to choose DMD NBS for research purposes (vs. 
when testing was for personal purposes). This finding suggests that those with related, even 
marginally so, health experiences think of NBS purposes differently. Focusing parents’ attention 
on personal benefits to NBS may increase utilization.  
The main effect of perceived vulnerability showed that participants whose hypothetical 
child had a family history of DMD were much more likely to choose DMD NBS than 
participants whose child had no DMD family history. Interestingly, unrelated family histories 
and health statuses influenced this choice; participants whose hypothetical newborn had either a 
family history of epilepsy or a premature birth were more likely to choose DMD NBS than 
participants whose child had no DMD family history, although this effect was smaller than for 
having a DMD family history. The Study 3 results suggest a gist reaction to a genetic 
vulnerability involving a similar part of the body (epilepsy history) or basic health vulnerability 
(premature birth), that is applied to vulnerability for other diseases (e.g. DMD). Health 
professionals should attend to patients’ perceived vulnerability of a disease when there is clear 
medical cause, as it influences testing decisions, attitudes towards the test and can change the 
way people feel about testing for research. However they should also attend to perceived 
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vulnerability when there are other, unrelated health risks that drive patients to conceive of an 
overall “vulnerable” state.  
Consistent Findings 
A consistent finding throughout the dissertation was that participants were more likely to 
choose DMD NBS if they reported higher importance of DMD NBS in general and seeing the 
DMD NBS results, and thought the results could inform future planning. They were less likely to 
choose DMD NBS if they had increased worry about the DMD NBS results. These results are 
consistent with previous research (DeLuca et al., 2011; Goddard, 2004; Parsons et al., 2006; 
Pelias, 2006; Waisbren et al., 2003). There were influences on these attitudes. In Study 1, 
participants who saw no mandatory NBS panel (vs. bundled or unbundled) thought DMD NBS 
was less important and would worry more about the DMD NBS results. In Study 3, participants 
given the DMD history scenario had the strongest attitudes about DMD NBS; they reported the 
highest importance of DMD NBS, seeing the DMD NBS results, and sharing the DMD NBS 
results, the greatest worry about the DMD NBS results, and that the results would prepare them 
for the future and affect whether they had more children the most.  
The subjective norm findings are consistent with previous theory and NBS research. 
Offering additional subjective norm information about parents akin to the participants did not 
have an effect, but participants’ own subjective norms about people important in their own lives 
had a very strong one. This finding supports the Theory of Reasoned Action, and mirrors 
previous research asserting that family members’ and friends’ experiences and opinions are very 
influential in NBS decision making (Bradley, 1993; Davey, 2005). Additionally, general 
subjective norms around NBS did not predict DMD NBS intent, but specific subjective norms 
around DMD NBS did; this indicates that subjective norms are topic-sensitive.  
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Strengths and Limitations 
There were multiple strengths of this dissertation. First, it addressed a timely topic for 
NBS in general and DMD NBS specifically. Over the past year DMD NBS has come to the 
forefront of optional NBS, with some researchers wanting it to be included in mandatory NBS 
panels and others calling for more evidence (American Journal of Medical Genetics, 2012). It is 
necessary to address the evidence base behind the NBS as well as the factors driving parents’ 
NBS decisions before making this change. Second, the vignettes and brochures were carefully 
crafted with the assistance of a pediatric decision making researcher (B.A. Tarini) and the 
Statewide Newborn Screening for Duchenne Muscular Dystrophy pilot program in Ohio 
(Mendell et al., 2012). Third, the theoretical framework was based on classic health behavior 
theory and grounded in previous NBS literature. Finally, the quantitative experimental design 
allowed me to cleanly vary specific influences on the NBS decision-making process with little 
threat to internal validity. I would not have been able to vary these factors using qualitative data 
collection. 
There are also weaknesses to be found in this dissertation. First, despite the effort made 
to ensure that study materials mirrored those used in real-world contexts, these Internet-
administered studies using hypothetical scenarios may not have evoked the same feelings or 
decision-making processes that would be present in a true population of DMD NBS decision 
makers, actual parents. Surveying actual parents with more emotional investment in newborn 
screening and possibly more knowledge may lead to more robust results, especially with the 
presence of a baby in the room during the decision. Second, although the focus of this 
experimentally-designed dissertation was to ensure internal validity, the non-generalizability of 
MTurk subjects is a threat to external validity. Their mere participation indicates that subjects 
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have the time and internet access to take an MTurk survey, and research has shown that MTurk 
subjects tend to be younger than the general public (Berinsky et al., 2011). This younger age may 
contribute to the significant age findings. Finally, by virtue of the study designs and study 
population, DMD NBS decision making was conceptualized as a solo process and not one done 
with partners and/or family members. A more likely scenario is a shared decision that includes at 
least two people (Epstein, 2013). In such a case the presence of additional decision makers may 
interact with some of the specific factors studied, emphasizing the influence of subjective norms 
and mitigating the influence one person’s perceived vulnerability. 
Implications 
This dissertation addressed the question of whether decisions are influenced by 
characteristics of test presentation and structure, using DMD NBS as a case study. The 
implications of the results are broad, ranging from improvements to the Theoretical Framework 
to suggestions for designing health communications related to NBS to advice for clinical 
practitioners. Many of these implications likely generalize beyond the field of NBS to any health 
context that includes optional testing.   
Implications for the Theoretical Framework 
 After collecting, analyzing, and interpreting the study data, it is necessary to re-visit the 
theoretical framework that informed this dissertation (Appendix A). Overall, this framework held 
as a way of conceptualizing the DMD NBS process into modifying factors, pre-test, and post-
test. The results of the three studies validated many of the constructs in the theoretical 
framework. Looking at the modifying factors, the results confirmed the influence of 
demographic characteristics, such as race and age, and personal history, such as previous 
pregnancy. Turning to pre-test factors, results supported the inclusion of subjective norms when 
103 
 
specific to participants’ own norms, and attitudes towards both NBS in general and DMD 
specifically, as these predicted DMD NBS choice throughout the three studies. The post-test 
factors were partially confirmed in Studies 2 and 3. Although results release did not have a 
significant main effect on DMD NBS choice in Study 2, the re-framing of the construct in Study 
3 as larger test purpose had significant interactions with perceived vulnerability. Additionally, 
attitudes of altruism, privacy, medical mistrust and government mistrust were inconsistently 
significant.  
However, the results suggest both changes to the theoretical framework, and directions 
for a new theoretical model. Although Study 1 showed a significant difference in DMD NBS 
choice between those who did not see a mandatory NBS panel and those who did (either bundled 
or unbundled), there was no difference between bundled and unbundled mandatory NBS panels. 
Thus the theoretical framework would best reflect these results if the bundling construct was 
modified as ‘context’, or the presence or absence of the mandatory NBS panel. Additionally, 
given the increasing number of optional NBS tests, a future theoretical framework might include 
the bundling of optional NBS offerings (as opposed to mandatory NBS panels). Such a construct 
would potentially tap into the cognitive-style variables such as decision fatigue. In addition, there 
might be a possible interaction of bundling with perceived vulnerability of the child: given the 
Study 3 results indicating a gist sense of perceived vulnerability, with more NBS tests to focus 
on, perceived vulnerability may increase. The perceived vulnerability factor would exist as a pre-
test factor in a modified framework. This construct would be predicted by personal history, as 
seen in Study 3, and knowledge. A last modification to the theoretical framework would be the 
use of subjective norms only as they are conceptualized by Theory of Reasoned Action and 
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supported by the results: as norms specific to the disease and to the person, and not general 
subjective norms.  
Implications for Health Communication 
It is important to understand the implications of the way in which we communicate 
information about optional NBS. First, if optional NBS is not presented in the context of 
mandatory NBS, these results suggest that participants’ NBS intention will be hindered and they 
will have more negative attitudes towards NBS. Second, these results suggest that future optional 
NBS program materials should be as specific as possible in the presentation of subjective norms. 
Developers should recognize that decision makers may not relate to the choices of unfamiliar, 
albeit similar, cases and pause before overemphasizing the benefit of common language such as 
“people like you”. Finally, these results suggest that optional NBS, even if in a research context, 
should not automatically be presented with a research focus. Such a presentation may not appeal 
to those with a perceived vulnerability to the disease being tested for. For those with a 
heightened personal stake in the disease, tests with a focus on personal purpose appear to be 
valued more.   
Clinical Implications 
In addition to the implications for the way in which materials present optional NBS 
information, these results have direct implications for the way in which doctors interact with 
parents making optional NBS decisions. First, when parents are making NBS decisions for their 
children, clinicians should consider assessing their perceived vulnerability to the specific disease 
as this may influence their decisions. Clinicians should also consider whether parents might have 
an overall, gist vulnerability stemming from another disease or health risk that could similarly 
influence the NBS decision. Once clinicians have an understanding of how vulnerable parents 
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perceive their child to be, they should have a conversation with the parents about the actual risk, 
especially if that perceived vulnerability stems from an unrelated disease or health issue. 
Correcting any misconceptions regarding risk may reduce optional NBS overuse (i.e., use by 
parents who are choosing testing for reasons unrelated to what the test can actually provide). 
Second, when recruiting parents for optional NBS programs clinicians should be cautious about 
appealing to parents’ sense of altruism, as this can backfire depending on the test result release 
and the parents’ actual altruism. Finally, careful attention must be paid to those with high 
medical mistrust. Clinicians should approach those with high medical mistrust knowing that this 
characteristic makes them less likely to choose NBS, and directly address any concerns of 
mistrust that may exist. 
Policy Implications  
As optional NBS is expanding it is important to consider the possible influences on 
decision makers before policies and universal guidelines are set. These results inform three larger 
policy implications for future optional NBS programs. First, there is a need to develop policies 
regarding the presentation of optional NBS. Although every state has a mandatory NBS program, 
there are variations in test offering and test presentation among states. These variations inhibit 
our ability to assess parental interest reliably and create the possibility of greater or lesser testing 
uptake simply due to structural differences in communications and program design. There is a 
need to promote consistency among optional NBS programs, including making sure to frame 
optional NBS within the context of mandatory NBS. Second, parents whose children have family 
history of related disease appeared to be less motivated by research-focused programs. This 
result suggests that optional NBS being conducted for research purposes will nonetheless have to 
call attention to how the NBS will have personal benefits to parents. And finally, the results 
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related to perceived vulnerability based on unrelated variables (e.g., other diseases) have 
implications for NBS policy. Those with unrelated disease histories reacted similarly to optional 
NBS decision making to those with related histories. As a result, future NBS policy might have 
to consider the potential for possible overuse of optional NBS based on an overall gist perception 
of vulnerability that is not clinically related to the conditions for which tests are being offered. 
For example, there may be a need to require that optional NBS programs for parents clarify how 
different factors that affect perceived child vulnerability (e.g., prematurity) do, or do not, affect 
the risk of the disease being tested for.  
Directions for Future Research 
The results of this dissertation have clear implications for future research. Now that we 
know optional testing is ideally presented in the context of mandatory testing, and given the 
growth of optional testing, a next step would be to study the bundling of multiple optional tests. 
More research is needed on bundling, and it may be worth looking to the future of multiple 
optional tests. After seeing the strong effect of perceived vulnerability in the study sample, it is a 
logical to use purposeful sampling of populations that perceive their children to be vulnerable for 
various reasons. In addition to a main effect, the study would test an interaction of vulnerability 
and optional test bundling. With the strong subjective norm results that included normative 
beliefs, further research is needed to identify the important others and address motivation to 
comply – exactly who are the people that influence decisions, and how does motivation to 
comply with their norms differ among different types of optional tests?    
While technology advances and optional NBS becomes both more available and less 
expensive, there is a potential for increased optional NBS use. DMD offered an exemplar to 
study the influences on optional NBS decision making, as knowing how such decisions do vary 
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by such features may inform future optional NBS practices. But with the push for DMD to 
become part of the mandatory NBS panel, it will be difficult to study it further as a purely 
optional NBS test. However, it is not just NBS that is expanding. After the mapping of the 
genome and the availability of commercialized genetic testing (e.g. 23andMe), the theoretical, 
clinical, health communication, and policy implications of optional NBS are also relevant for 
other optional genetic testing. Thus we can study the constructs significant in NBS decision 
making, like bundling and perceived vulnerability, in other genetic testing contexts. Such study 
will allow us to understand the influence of test structure and presentation characteristics on 
patient utilization of genetic tests, and help guide clinical and health communication practice as 












Appendix B. Preliminary Study Vignettes (Experimental Conditions 1-3) 
 
Imagine that you or your partner has just given birth to a baby boy. A nurse comes into your 
room to tell you that the hospital has developed a new test that screens newborn babies for DMD. 
DMD cannot be cured and the symptoms cannot be prevented. The test requires a blood sample 
but causes no long-term harm or side effects. The test will not cost any money.  
 
[Condition 1 text] All newborn babies in the state are mandated to be screened for certain 
diseases. In the hospital after birth he will have a little blood drawn as part of that screening. 
Using this blood sample, doctors will test for about 49 of these genetic diseases. The sample can 
also be used to test for Duchenne’s. Adding the screening test for Duchenne’s will not require 
you to come to the hospital at an additional time or draw more blood. The results will be 
automatically released to you. You will need to check a box on the medical chart form. 
 
[Condition 2 text] All newborn babies in the state are mandated to be screened for certain 
diseases. In the hospital after birth he will have a little blood drawn as part of that screening. 
Using this blood sample, doctors will test the following genetic diseases:  
 
Amino Acid Disorders       Organic Acid Disorders 
1. Argininemia       26. 2-Methyl-3-hydroxy butyric aciduria 
2. Argininosuccinic acidemia     27. 2- Methylbutyryrl-CoA dehydrogenase deficiency 
3. Citrullinemia        28. 3-Hydroxy 3-methylglutaric aciduria 
4. Citrullinemia type II       29. 3-Methylcrotonyl-CoA carboxylase deficiency 
5. Homocystinuria      30. 3-Methylglutaconic aciduria 
6. Hypermethioninemia      31. Beta-ketothiolase deficiency 
7. Maple syrup urine disease (MSUD)    32. Glutaric acidemia type I 
8. Phenylketonuria (PKU)       33. Isobutyryl-CoA dehydrogenase deficiency 
9. Benign hyperphenylalaninemia defect    34. Isovaleric acidemia 
10. Biopterin cofactor biosynthesis defect    35. Malonic acidemia 
11. Biopterin cofactor regeneration defect    36. Methylmalonic academia (Cbl A,B) 
12. Tyrosinemia type I       37. Methylmalonic academia (Cbl C,D) 
Fatty Acid Oxidation Disorders     38. Methylmalonic acidemia (Mutase deficiency) 
13. Carnitine acylcarnitine translocase deficiency    39. Multiple carboxylase deficiency 
14. Carnitine palmitoyl transferase I deficiency    40. Propionic acidemia 
15. Carnitine palmitoyl transferase II deficiency  Endocrine Disorder 
16. Carnitine uptake defect    41. Congenital adrenal 
17. Dienoyl-CoA reductase deficiency    42. Congenital hypothyroidism (CH) hyperplasia (CAH) 
18. Glutaric acidemia type II    Hemoglobinopathies 
19. Long-chain L-3-hydroxy acyl-CoA dehydrogenase deficiency 43. S/Beta thalassemia 
20. Medium/short-chain L-3-hydroxy acyl-CoA   44. S/C disease 
dehydrogenase deficiency    45. Sickle cell anemia 
21. Medium-chain acyl-CoA dehydrogenase deficiency   46. Variant hemoglobinopathies 
22. Medium-chain ketoacyl-CoAthiolase deficiency   Other Disorders 
23. Short-chain acyl-CoA dehydrogenase deficiency   47. Biotinidase deficiency 
24. Trifunctional protein deficiency    48. Cystic Fibrosis 
25. Very long-chain acyl-CoA dehydrogenase deficiency   49. Galactosemia 
 
The sample can also be used to test for Duchenne’s. Adding the screening test for Duchenne’s 
will not require you to come to the hospital at an additional time or draw more blood. However, 
because the test is new, even though the results are available they are not automatically released. 
If you would like to learn the results of the test then you need to fill out a form, have 
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your pediatrician sign it, and mail it to the hospital laboratory to make a special request after the 
test has been done and the results are ready. 
 
[Condition 3 text] The test for Duchenne’s requires a special request, and you will have to bring 




Appendix C. Study 1 Vignettes (Experimental Conditions 1-5) 
 
Duchenne muscular dystrophy (Duchenne’s) is a disease that causes muscles to deteriorate 
and weaken. Duchenne’s is a genetic disease and primarily affects boys. The symptoms of 
Duchenne’s develop in early childhood (about age 2-5). Most people with Duchenne’s are unable 
to walk by the time they are a young adult. By the end of their life, most people need respirators 
to breathe. There is no cure for Duchenne’s and most people with Duchenne’s die in their 20s or 
30s.   
  
Imagine that you or your partner has just given birth to a baby boy. A nurse comes into your 
room to tell you that there is a new test that screens newborn babies for Duchenne’s. Duchenne’s 
cannot be cured and the symptoms cannot be prevented, but the test may help you plan for the 
future. The test requires a blood sample but causes no long-term harm or side effects. The test 
will not cost any money.  
 
[Condition 1 text] All newborn babies in Michigan are mandated to be screened for certain 
diseases. In the hospital after birth your baby will have a little blood drawn as part of that 
screening. Using this blood sample, doctors will test for about 49 of these genetic diseases. The 
sample can also be used to test for Duchenne’s. Adding the screening test for Duchenne’s will 
not require you to come to the hospital at an additional time or draw more blood. The results 
from the Duchenne’s test will be released to you at the same time as the results from the other 
screening tests.   
 
[Condition 2 text] All newborn babies are mandated to be screened for certain diseases. In the 
hospital after birth your baby will have a little blood drawn as part of that screening. Using this 
blood sample, doctors will test for about 49 of these genetic diseases. The sample can also be 
used to test for Duchenne’s. Adding the screening test for Duchenne’s will not require you to 
come to the hospital at an additional time or draw more blood. You will receive the results from 
the Duchenne’s test separately from the other results after a short delay. 
 
[Condition 3 text] All newborn babies are mandated to be screened for certain diseases. In the 
hospital after birth your baby will have a little blood drawn as part of that screening. Using this 
blood sample, doctors will test the following genetic diseases:  
 
Amino Acid Disorders Organic Acid Disorders 
1. Argininemia 26. 2-Methyl-3-hydroxy butyric aciduria 
2. Argininosuccinic acidemia 27. 2- Methylbutyryrl-CoA dehydrogenase deficiency 
3. Citrullinemia   28. 3-Hydroxy 3-methylglutaric aciduria 
4. Citrullinemia type II 29. 3-Methylcrotonyl-CoA carboxylase deficiency 
5. Homocystinuria  30. 3-Methylglutaconic aciduria 
6. Hypermethioninemia 31. Beta-ketothiolase deficiency 
7. Maple syrup urine disease (MSUD) 32. Glutaric acidemia type I 
8. Phenylketonuria (PKU) 33. Isobutyryl-CoA dehydrogenase deficiency 
9. Benign hyperphenylalaninemia defect 34. Isovaleric acidemia 
10. Biopterin cofactor biosynthesis defect 35. Malonic acidemia 
11. Biopterin cofactor regeneration defect 36. Methylmalonic academia (Cbl A,B) 
12. Tyrosinemia type I 37. Methylmalonic academia (Cbl C,D) 
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Fatty Acid Oxidation Disorders   38. Methylmalonic acidemia (Mutase deficiency) 
13. Carnitine acylcarnitine translocase deficiency   39. Multiple carboxylase deficiency 
14. Carnitine palmitoyl transferase I deficiency   40. Propionic acidemia 
15. Carnitine palmitoyl transferase II deficiency Endocrine Disorder 
16. Carnitine uptake defect  41. Congenital adrenal 
17. Dienoyl-CoA reductase deficiency 42. Congenital hypothyroidism (CH) hyperplasia (CAH) 
18. Glutaric acidemia type II Hemoglobinopathies 
19. Long-chain L-3-hydroxy acyl-CoA dehydrogenase  
deficiency 
43. S/Beta thalassemia 
20. Medium/short-chain L-3-hydroxy acyl-CoA 
dehydrogenase deficiency  
44. S/C disease 
45. Sickle cell anemia 
21. Medium-chain acyl-CoA dehydrogenase deficiency 46. Variant hemoglobinopathies 
22. Medium-chain ketoacyl-CoAthiolase deficiency Other Disorders 
23. Short-chain acyl-CoA dehydrogenase deficiency 47. Biotinidase deficiency 
24. Trifunctional protein deficiency 48. Cystic Fibrosis 
25. Very long-chain acyl-CoA dehydrogenase deficiency 49. Galactosemia 
 
The sample can also be used to test for Duchenne’s. Adding the screening test for 
Duchenne’s will not require you to come to the hospital at an additional time or draw more 
blood. The results from the Duchenne’s test will be automatically released to you at the same 
time as the results from the other screening tests.   
 
[Condition 4 text] All newborn babies in Michigan are mandated to be screened for certain 
diseases. In the hospital after birth your baby will have a little blood drawn as part of that 
screening. Using this blood sample, doctors will test the following genetic diseases:  
 
Amino Acid Disorders Organic Acid Disorders 
1. Argininemia 26. 2-Methyl-3-hydroxy butyric aciduria 
2. Argininosuccinic acidemia 27. 2- Methylbutyryrl-CoA dehydrogenase deficiency 
3. Citrullinemia   28. 3-Hydroxy 3-methylglutaric aciduria 
4. Citrullinemia type II 29. 3-Methylcrotonyl-CoA carboxylase deficiency 
5. Homocystinuria  30. 3-Methylglutaconic aciduria 
6. Hypermethioninemia 31. Beta-ketothiolase deficiency 
7. Maple syrup urine disease (MSUD) 32. Glutaric acidemia type I 
8. Phenylketonuria (PKU) 33. Isobutyryl-CoA dehydrogenase deficiency 
9. Benign hyperphenylalaninemia defect 34. Isovaleric acidemia 
10. Biopterin cofactor biosynthesis defect 35. Malonic acidemia 
11. Biopterin cofactor regeneration defect 36. Methylmalonic academia (Cbl A,B) 
12. Tyrosinemia type I 37. Methylmalonic academia (Cbl C,D) 
Fatty Acid Oxidation Disorders   38. Methylmalonic acidemia (Mutase deficiency) 
13. Carnitine acylcarnitine translocase deficiency   39. Multiple carboxylase deficiency 
14. Carnitine palmitoyl transferase I deficiency   40. Propionic acidemia 
15. Carnitine palmitoyl transferase II deficiency Endocrine Disorder 
16. Carnitine uptake defect  41. Congenital adrenal 
17. Dienoyl-CoA reductase deficiency 42. Congenital hypothyroidism (CH) hyperplasia (CAH) 
18. Glutaric acidemia type II Hemoglobinopathies 
19. Long-chain L-3-hydroxy acyl-CoA dehydrogenase 
deficiency 
43. S/Beta thalassemia 
20. Medium/short-chain L-3-hydroxy acyl-CoA 
dehydrogenase deficiency  
44. S/C disease 
45. Sickle cell anemia 
21. Medium-chain acyl-CoA dehydrogenase deficiency 46. Variant hemoglobinopathies 
22. Medium-chain ketoacyl-CoAthiolase deficiency Other Disorders 
23. Short-chain acyl-CoA dehydrogenase deficiency 47. Biotinidase deficiency 
24. Trifunctional protein deficiency 48. Cystic Fibrosis 
25. Very long-chain acyl-CoA dehydrogenase deficiency 49. Galactosemia 
 
The sample can also be used to test for Duchenne’s. Adding the screening test for 
Duchenne’s will not require you to come to the hospital at an additional time or draw more 
blood. You will receive the results from the Duchenne’s test separately from the other test results 
after a short delay.    
 
[Condition 5 text] The test for Duchenne’s can be done in the hospital after birth. The results 
from the test will be automatically released to you.  
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Appendix D. Study 1 Brochures 

















Appendix E. Survey Measures 
Measure Item/Scale Response Options Citation 
Primary outcome 
DMD test utilization How likely do you think that it is that you will choose 






Attitudes & beliefs 
DMD NBS - 
importance 






DMD NBS - 
importance 
How important is it that you see the results from your 
baby’s test for DMD? 






DMD NBS - 
importance 
How important is it to share the results from the DMD 
test with others? 






DMD NBS - impact How much do you think you would worry about the 
results of your baby’s DMD test? 









DMD NBS - impact The information from the DMD test may help me 







DMD NBS - impact The information from the DMD test would affect 















DMD NBS - impact My child would be treated differently by others if he is 







NBS in general Do you think your child will be treated differently by 







NBS in general Do you think having a child with an incurable disease 







Information How important is it that you have all the information 
available about your child? 












Do you think that most people agree or disagree that it 
is important for babies to be tested for as many genetic 
diseases as possible?  









Subjective norm  
re: DMD test 
(direct measure) 
Do you think that most people agree or disagree with 
getting the DMD test? 










Age What is your age? Open ended  
Gender What is your gender? Male; Female  
Educational 
attainment 
What is the highest level of education that you have 
received? 
Less than high school; High 
school graduate; College 
graduate; More than college 
 
Marital status What is your marital status? Married/partnered; 
Not married/partnered 
 
Household income Including all sources of income, what is your total 
household income? 
Less than $14,500;  
$14,500- less than $35,000;  
$35,000- less than $50,000;  
$50,000-less than $75,000;  
$75,000-less than $100,000;  












Hawaiian and Other Pacific 





Experience in the 
health field  
What is your experience working in the health or 
research field? 
Currently working in the 
health or research field; 
Previously worked in the 
health or research field; 
Never worked in the health 
or research field 
Created 
Pregnancy history Have you or your partner ever been pregnant? Yes; No; Don’t know   Created 




Have you had any complications during a pregnancy? Yes; No; Don’t know   Created 
Prenatal screening 
history  
Have you ever had any prenatal screening tests done 
during a pregnancy? 
Yes; No; Don’t know   Created 
Newborn screening 
history 
Did your child/children have newborn screening tests 
done? 
Yes; No; Don’t know   Created 
Child health history Has your child/children had any illnesses? Acute illness; Chronic 
illness; Both an acute illness 




people with chronic 
illnesses 
Do you know someone with a chronic illness? Yes; No; Don’t know Created 
Familiarity with the 
disease 
Do you know of a family member or friend diagnosed 
with DMD or another genetic disorder? 
Yes, a family member; Yes, 
a friend; No; Don’t know 
Created 
Individual differences 
Cognitive Style Please answer the following questions about yourself: 
1. I like to have the responsibility of handling a 
situation that requires a lot of thinking. 
2. Thinking is not my idea of fun. (reverse coded) 
1=Strongly Disagree 
2=Disagree 
3=Neither Agree nor 
Disagree 
4=Agree  
Need for Cognition 





3. I would rather do something that requires little 
thought than something that is sure to challenge my 
thinking abilities. (reverse coded) 
4. The idea of relying on thought to make my way to 
the top appeals to me. 
5. I really enjoy a task that involves coming up with 
new solutions to problems.  
6. Learning new ways to think doesn’t excite me very 
much. (reverse coded) 




The final score is a sum of 
each of the 7 items 
Monitoring/blunting 
coping style 
Different people tend to respond in different ways 
when faced with difficult or threatening situations. The 
following question describes a possible difficult 
situation which you may encounter. Please consider 
each scenario and indicate how you think you would 
react. 
 
Vividly imagine that you are afraid of the dentist and 
have to get some dental work done. Which of the 
following would you do? Tick all of the statements  
that might apply to you: 
1. I would ask the dentist exactly what he was going 
to do. (M) 
2. I would take a tranquilizer or have a drink before 
going. (B) 
3. I would try to think about pleasant memories. (B) 
4. I would want the dentist to tell me when I would 
feel pain. (M) 
5. I would try to sleep. (B) 
Items are marked as 
Monitoring (M) or Blunting 
(B). To obtain the total 
score, add up all the M 
scores and B scores and 
subtract the Total B score 
from the Total M. The 
higher (more positive) the 







6. I would watch all the dentist’s movements and 
listen for the sound of the drill. (M) 
7. I would watch the flow of water from my mouth to 
see if it contained blood. (M) 
8. I would do mental puzzles in my mind. (B) 
Altruism Check the category on the right that conforms to the 
frequency with which you have carried out the 
following acts: 
1. I have donated goods or clothes to a charity. 
2. I have done volunteer work for a charity. 
3. I have delayed an elevator and held the door open 
for a stranger. 
4. I have allowed someone to go ahead of me in a line 
(e.g., supermarket, copying machine, etc.). 
5. I have bought “charity” Christmas cards 
deliberately because I knew it was for a good cause. 
6. I have helped a classmate who I did not know that 
well with a homework assignment when my 
knowledge was greater than his or hers. 
7. I have, before being asked, voluntarily looked after 
a neighbor’s pets or children without being paid for 
it. 
8. I have offered to help a handicapped or elderly 







An overall score is 






Privacy Here are some statements about personal information. 
From the standpoint of personal privacy, please 
indicate the extent to which you, as an individual, agree 
or disagree with each statement. 











Smith et al (1996) 
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2.  When companies ask me for personal information, 
I sometimes think twice before providing it. 
3. It bothers me to give personal information to so 
many companies. 
4. I am concerned that companies are collecting too 
much personal information about me. 
6=Strongly Agree 
 
An overall score is 
calculated by averaging the 
items. 
Medical Distrust The next questions are about your opinion of the health 
care system in general. When we refer to the health 
care system, we mean hospitals, health insurance 
groups, and medical research. For each statement 
below, please check how strongly you agree or 
disagree: 
1. Medical experiments can be done on me without 
my knowing about it. 
2. My medical records are kept private. (reverse 
coded) 
3. People die every day because of mistakes by the 
health care system.  
4. When they take my blood, they do tests they don’t 
tell me about.  
5. If a mistake were made in my health care, the health 
care system would try to hide it from me.  
6. People can get access to my medical records 
without my approval.  
7. The health care system cares more about holding 
costs down than it does about doing what is needed 
for my health.  
8. I receive high-quality medical care from the health 
care system. (reverse coded) 







An overall score is 








Health Care System 
Distrust Scale 
Rose et al (2004) 
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above all other considerations when treating my 
medical problems. (reverse coded) 
10. Some medicines have things in them that they don’t 
tell you about.  
Government Distrust How much do you agree or disagree with the following 
statements? 
1.When there is a really serious health or environmental 
problem, then public officials will take care of it.  
2.Until they alert me about a specific problem, I don't 
really have to worry. 
3.I have very little control over risks to my health. 
4.Those in power often withhold information about 
things that are harmful to us. 
5.The land, air, and water around us are, in general, 
more contaminated now than ever before. 
6.Continued economic growth can only lead to 
pollution and depletion of natural resources. 





An overall score is 
calculated by averaging the 
items. 





Appendix F. Study 2 Vignettes (Experimental Conditions 1-5) 
 
Duchenne muscular dystrophy (Duchenne’s) is a disease that causes muscles to deteriorate 
and weaken. Duchenne’s is a genetic disease and primarily affects boys. The symptoms of 
Duchenne’s develop in early childhood (about age 2-5). Most people with Duchenne’s are unable 
to walk by the time they are a young adult. By the end of their life, most people need respirators 
to breathe. There is no cure for Duchenne’s and most people with Duchenne’s die in their 20s or 
30s.   
 
Imagine that you or your partner has just given birth to a baby boy. A nurse comes into your 
room to tell you that there is a new test that screens newborn babies for Duchenne’s. Duchenne’s 
cannot be cured and the symptoms cannot be prevented, but the test may help you plan for the 
future. The test requires a blood sample but causes no long-term harm or side effects. The test 
will not cost any money. 
 
[Condition 1 text] If you choose to have the test done, the hospital nurse will draw a blood 
sample which will then be sent to a private testing company to be tested for Duchenne’s. The test 
results will be given to you personally, which means that the results will not be entered into your 
baby’s medical record and will not be available to doctors, or anyone else, unless you grant them 
access.  
 
[Condition 2 text] If you choose to have the test done, the hospital nurse will draw a blood 
sample, which will then be tested for Duchenne’s. The test results will be entered into your 
baby’s confidential personal health record, which means that only people with access to your 
baby’s personal health record will be able to see the results. 
 
[Condition 3 text] If you choose to have the test done, the hospital nurse will draw a blood 
sample, which will then be tested for Duchenne’s. The test results will be entered into your 
baby’s personal health record, which means that only people with access to your baby’s personal 
health record will be able to see the results. You can also choose to have part of the blood sample 
be stored in the hospital to be used in future medical research studies which may develop new 
testing and treatment options for Duchenne’s.  
 
[Condition 4 text] If you choose to have the test done, the hospital nurse will draw a blood 
sample, which will then be tested for Duchenne’s. The test results will be entered into your 
baby’s confidential personal health record, which means that only people with access to your 
baby’s personal health record will be able to see the results. You can also choose to have the 
results entered into a national registry specifically of newborns with Duchenne’s, which may 
lead to a better understanding of Duchenne’s testing and treatment options for children living 
with Duchenne’s, including possibly your child.
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[Condition 5 text] If you choose to have the test done, the hospital nurse will draw a blood 
sample, which will then be tested for Duchenne’s. The test results will be entered into your 
baby’s confidential personal health record, which means that only people with access to your 
baby’s personal health record will be able to see the results. You can also choose to have the 
results entered into a national registry of all newborns, which follow trends in children’s health 
and lead to a better understanding of general medical care. 
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Appendix G. Study 2 Brochures 
Brochure: Private Release 
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Appendix H. Study 3 Vignettes (Experimental Conditions 1-8) 
 
Duchenne muscular dystrophy (Duchenne’s) is a disease that causes muscles to deteriorate 
and weaken. Duchenne’s is a genetic disease and primarily affects boys. The symptoms of 
Duchenne’s develop in early childhood (about age 2-5). Most people with Duchenne’s are unable 
to walk by the time they are a young adult. By the end of their life, most people need respirators 
to breathe. There is no cure for Duchenne’s and most people with Duchenne’s die in their 20s or 
30s.   
 
[Condition 1 text] Imagine you or your partner gave birth to a baby boy yesterday. He was born 
full-term at 40 weeks and is a healthy 20 inches and 8 pounds. Your doctor has no concerns 
about his immediate health. You and your son will be released from the hospital tomorrow. 
 
While you are sitting in your hospital room, a nurse comes into your room to discuss a type of 
test for newborn babies that the hospital is offering are offering parents. She tells you that a new 
test has been developed that screens newborn babies for Duchenne’s Muscular Dystrophy 
(DMD) and gives you information about the test. 
 
[Condition 2 text] Imagine you or your partner gave birth to a baby boy yesterday. He was born 
full-term at 40 weeks and is a healthy 20 inches and 8 pounds. Your doctor has no concerns 
about his immediate health. You and your son will be released from the hospital tomorrow.  
 
One thing you are concerned about is your family history of a genetic disorder called 
Duchenne’s Muscular Dystrophy (DMD). Your uncle (on your mother’s side) was diagnosed 
with DMD at age 3 and by age 12 was wheelchair dependent due to muscle deterioration. Your 
uncle was eventually paralyzed and died from DMD at age 20.  
 
While you are sitting in your hospital room, a nurse comes into your room to discuss a type of 
test for newborn babies that the hospital is offering are offering parents. She tells you that a new 
test has been developed that screens newborn babies for DMD and gives you information about 
the test. 
 
[Condition 3 text] Imagine you or your partner gave birth to a baby boy yesterday. He was born 
full-term at 40 weeks and is a healthy 20 inches and 8 pounds. Your doctor has no concerns 
about his immediate health. You and your son will be released from the hospital tomorrow. 
 
One thing you are concerned about is your family history of Epilepsy, a neurological disorder 





While you are sitting in your hospital room, a nurse comes into your room to discuss a type of 
test for newborn babies that the hospital is offering are offering parents. She tells you that a new 
test has been developed that screens newborn babies for Duchenne’s Muscular Dystrophy 
(DMD) and gives you information about the test. 
 
[Condition 4 text] Imagine you or your partner gave birth to a baby boy yesterday. He was born 
prematurely, at 33 weeks instead of the expected 40. He is 17 inches and 4 pounds, compared to 
full-term babies’ average size of 20 inches and 8 pounds. . Because your son was born 
prematurely, your doctor has important concerns about his immediate health. You will be able to 
leave the hospital tomorrow, but your son will need to stay in the hospital for another week.   
 
There are several issues with your son that you are concerned about because of his premature 
birth. In particular, he has difficulty feeding and sometimes needs to be fed through a temporary 
tube through his mouth. You know that he will need to be able to feed without help before he can 
go home. He will also have to be followed for a few years to make sure that he does not develop 
any cognitive or physical developmental problems.  
 
While you are sitting in your hospital room, a nurse comes into your room to discuss a type of 
test for newborn babies that the hospital is offering are offering parents. She tells you that a new 
test has been developed that screens newborn babies for Duchenne’s Muscular Dystrophy 
(DMD), a genetic condition that causes all muscles in the body to become weak over time, and 
gives you information about the test. 
 
[Condition 5 text] Imagine you or your partner gave birth to a baby boy yesterday. He was born 
full-term at 40 weeks and is a healthy 20 inches and 8 pounds. Your doctor has no concerns 
about his immediate health. You and your son will be released from the hospital tomorrow. 
 
While you are sitting in your hospital room, a nurse comes into your room to discuss that 
researchers at a local university are offering parents. She tells you that a new test has been 
developed that screens newborn babies for Duchenne’s Muscular Dystrophy (DMD) and gives 
you information about the test. 
 
[Condition 6 text] Imagine you or your partner gave birth to a baby boy yesterday. He was born 
full-term at 40 weeks and is a healthy 20 inches and 8 pounds. Your doctor has no concerns 
about his immediate health. You and your son will be released from the hospital tomorrow.  
 
One thing you are concerned about is your family history of a genetic disorder called 
Duchenne’s Muscular Dystrophy (DMD). Your uncle (on your mother’s side) was diagnosed 
with DMD at age 3 and by age 12 was wheelchair dependent due to muscle deterioration. Your 
uncle was eventually paralyzed and died from DMD at age 20.  
 
While you are sitting in your hospital room, a nurse comes into your room to discuss that 
researchers at a local university are offering parents. She tells you that a new test has been 




[Condition 7 text] Imagine you or your partner gave birth to a baby boy yesterday. He was born 
full-term at 40 weeks and is a healthy 20 inches and 8 pounds. Your doctor has no concerns 
about his immediate health. You and your son will be released from the hospital tomorrow. 
 
One thing you are concerned about is your family history of Epilepsy, a neurological disorder 
that causes seizures. Both your father and your father’s sister have a medical history of having 
seizures.  
 
While you are sitting in your hospital room, a nurse comes into your room to discuss that 
researchers at a local university are offering parents. She tells you that a new test has been 
developed that screens newborn babies for Duchenne’s Muscular Dystrophy (DMD) and gives 
you information about the test. 
 
[Condition 8 text] Imagine you or your partner gave birth to a baby boy yesterday. He was born 
prematurely, at 33 weeks instead of the expected 40. He is 17 inches and 4 pounds, compared to 
full-term babies’ average size of 20 inches and 8 pounds. . Because your son was born 
prematurely, your doctor has important concerns about his immediate health. You will be able to 
leave the hospital tomorrow, but your son will need to stay in the hospital for another week.   
 
There are several issues with your son that you are concerned about because of his premature 
birth. In particular, he has difficulty feeding and sometimes needs to be fed through a temporary 
tube through his mouth. You know that he will need to be able to feed without help before he can 
go home. He will also have to be followed for a few years to make sure that he does not develop 
any cognitive or physical developmental problems.  
 
While you are sitting in your hospital room, a nurse comes into your room to discuss that 
researchers at a local university are offering parents. She tells you that a new test has been 
developed that screens newborn babies for Duchenne’s Muscular Dystrophy (DMD), a genetic 
condition that causes all muscles in the body to become weak over time, and gives you 
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